Back to GetFilings.com

(Exact Name of Registrant as Specified in its Charter)

(Address of Principal Executive Offices and Zip Code)

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirement for the past 90 days.

Yes    X            No

Number of shares outstanding of the issuer's Common Stock, par value $.01 per share, as of March 31, 2004: 9,050,323 shares.

Our discovery informatics and discovery research products and services enable life science companies to enhance their drug discovery capabilities. We combine our resources in computer-aided molecular design, cheminformatics, chemistry research and production, with scientists on our staff who possess the hands-on understanding of the challenges facing pharmaceutical research organizations to deliver products and services internationally recognized for their innovation and quality. By formulating new chemical compounds and aiding our partners' design of new chemical compounds in ways that are more likely to result in drug discoveries, we offer our customers advantages in terms of research cycle time, cost, and efficiency of research activities.

We have formed commercial relationships with most major pharmaceutical companies and with many emerging biotechnology companies based on their use of some or all of our products and services. In addition, we have established strategic collaborations with several of the companies based on our specific unique capabilities.

Tripos was formed in 1979 to commercialize software for molecular visualization, analysis and design. In building our discovery services and enterprise consulting capabilities, we have focused on developing an integrated suite of offerings and on applying disciplined financial management intended to result in positive contributions to profitability and cash flows while simultaneously investing to stay at the leading edge of scientific research. In addition to creating product and service offerings, our chemistry research activities have created an opportunity for us to participate in therapeutic collaborations with certain of our customers, giving us an ownership and/or royalty interest in select early-stage new drug candidates.

Our business model is based primarily on deriving recurring revenues from our discovery informatics and discovery research businesses and secondarily on achieving contributions from therapeutic collaborations if and when new therapeutics are developed. The following is a description of each area of our business:

1. Discovery Informatics Products. The SYBYL® and UNITY® software suites are the core of our discovery software offerings. These suites provide integrated tools for computer-aided molecular modeling and visualization, visual screening, combinatorial library design, data storage and analysis, and structure-activity relationships to customers in pharmaceutical, biotechnology and related life science fields of research. We offer over fifty (50) software products for these research areas.
2. Discovery Informatics Services. Through our consulting, we design and build systems that enable management and analysis of the vast amounts of data generated by high-throughput technologies in genomics, proteomics, chemistry, and biology. We deploy our MetaLayerä software (a middleware product) to integrate chemistry and biology data of disparate types, along with AUSPYXä data cartridge technology, ChemCoreRIOä , ModelBASEä , LITHIUMä, FormsBUILDERä and our electronic notebook technologies to aid clients with their discovery process management.
3. Discovery Research Products and Services. Tripos Receptor Research laboratories, based in the United Kingdom, offer compound design and synthesis, molecular analysis and a complete suite of lead

Item 1. Financial Statements (continued)

We have a geographically diverse customer base, with over half of our revenues derived from customers outside of North America. Our worldwide sales force operates from offices in the United States, Canada, England, France, and Germany, and through representatives around the remainder of the Pacific Rim. Our headquarters is in St. Louis, Missouri and our chemistry laboratory is in Cornwall, England.

The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all normal recurring adjustments necessary for a fair presentation of such financial statements have been included. Operating results for the three-month period ended March 31, 2004 are not necessarily indicative of the results that may be expected for the year ending December 31, 2004.

We account for stock option plans under the intrinsic value method as permitted under Accounting Principles Board Opinion No. 25 ("APB 25"), "Accounting for Stock Issued to Employees", and related Interpretations. Under APB 25, generally no compensation expense is recognized because the exercise price of the options equal the fair value of the stock at the grant date.

The following table illustrates the effect on net income and earnings per share for the three-months ended March 31, 2004 and 2003 if the Company had applied the fair value recognition provisions of SFAS 123, "Accounting for Stock-Based Compensation", to stock-based employee compensation.

The provision for income taxes is computed using the liability method. The primary difference between financial statement and taxable income results from the use of different methods of computing capitalized development costs, accrued expenses, depreciation and the valuation of certain tax credits and net operating losses. The effective tax rate for 2004 reflects management's current estimate of the distribution of earnings among the statutory jurisdictions in which we operate and the valuation of certain tax credits and net operating losses in the U.S. and U.K. from prior tax years (each ending December 31). A valuation allowance was established for deferred tax assets related to the prior years' net operating losses, but does not impair our ability to use those deferred tax assets upon achieving profitability in the related jurisdictions. Upon the recognition of income in future periods in the jurisdictions where the deferred tax assets were created, release of the corresponding valu ation allowances may result in a lower effective tax rate.

The components of comprehensive income, net of related tax, for the three-month periods ended March 31, 2004 and 2003 are as follows:

The components of accumulated other comprehensive income, net of related tax, at March 31, 2004 and December 31, 2003 are as follows:

During the first quarter of 2004, revenues from Pfizer, Inc. represented 57% of total net sales. For the same period in 2003, Pfizer represented 45% of total net sales. No other customers represented over 10% of total net sales in either period. We have provided products and services to Pfizer under three separate contracts: multi-year worldwide licenses to our discovery software products, multi-year collaborative software development project and a $90 million four-year discovery research project to design and synthesize exclusive compound libraries. The four-year discovery research project to design and synthesize chemical compounds ("file enrichment") was amended in the first quarter of 2004 from its original $100 million revenue potential to the current $90 million target. Tripos will reduce file enrichment activities with Pfizer, but will engage in new work in the areas of hit follow-up and large library production, the next steps in the drug discovery process that follow directly from screening library compounds. The bulk of the resulting decrease in the total contract value, will occur in 2005.

(5)     Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share for the quarters ended March 31, 2004 and 2003.

Note A: For the three-month period in 2004, weighted average shares outstanding did not include the effect of employee stock options as their inclusion would have been anti-dilutive.

For additional disclosures regarding earnings per share, see the notes to the Company's 2003 consolidated financial statements in its Form 10-K.

We maintain a physical inventory of chemical compound libraries in various states of completion. Costs associated with the manufacture of compounds are calculated using the standard cost method and are carried at the lower of cost (standard cost method approximating FIFO) or market. Compounds that are acquired from third parties are also carried at the lower of cost or market. In calculating the reserve for obsolescence, collections of compounds are reviewed for their age and cumulative sales trends, and if necessary, a reserve provision is made for each collection or library of compounds. If there is, in our opinion, a significant adverse deviation in sales trends for a specific compound collection or library, an additional reserve provision is taken. Work in process and finished goods inventory includes the accumulated cost of compounds in production or awaiting shipment to customers under discovery research or custom synthesis contracts. Inventory balances at March 31, 2004 and Dece mber 31, 2003 are:

Certain time-based software license arrangements are covered by non-cancelable agreements whose terms range from one to five years. The average term of the contracts is three years. Revenue from these time-based software license arrangements is recognized ratably over the agreed term. The following table shows the amount of future revenues to be recognized from these non-cancelable arrangements as of March 31, 2004.

	Revenues to be recognized in:	Amount
	2004, over remaining nine months	$ 9,412
	2005	5,062
	2006	2,024
	2007	164
	Total	$ 16,662

Tripos is typically paid annually under these contracts. Shown below are the amounts to be billed under these contracts subsequent to March 31, 2004 (amounts not included in the accompanying balance sheets at March 31, 2004).

	Amounts to be billed in:	Amount
	2004, over remaining nine months	$ 6,237
	2005	2,293
	2006	1,357
	Total	$ 9,887

We have existing credit facilities provided by LaSalle Bank in the form of a revolving line of credit and a mortgage loan for our corporate headquarters building. The credit facilities are collateralized by substantially all of our U.S. assets and stock pledges for each of the U.S. and U.K. subsidiaries.

The mortgage note calls for even quarterly principal payments based on a twenty-year amortization schedule. Borrowings under the mortgage are subject to a variable interest rate at LIBOR plus 2.25%. Interest rates paid by the Company on the mortgage have averaged just over 3.4% during 2003 and early 2004. The maturity date of the mortgage facility is December 2, 2005. As of March 31, 2004, $4,078 was remaining on the mortgage.

The Company and LaSalle Bank entered into an amendment to the existing credit facility in April 2004, the modified facility remains at $6,000 and is a one-year commitment with a 25 basis point increase in associated fees. The amended facility addresses the Company's reduced requirement to fund capital expenditures through bank debt while continuing to meet working capital funding needs. Covenants under the revolving facility include minimum interest coverage, minimum shareholders' equity and an annual clean down period of 30 consecutive days in which no borrowings are outstanding. The line of credit carries a commitment fee of 3/8% of the unused portion of the line. At March 31, 2004, we had outstanding borrowings of $4,500. We were in compliance with the revised covenants under the amended credit facility as of March 31, 2004, which was the first covenant measurement date. Due to the one-year commitment of the amended credit facility, draws on the line of credit are classified as short-te rm debt.

During 2001 and 2002 Tripos made in-kind contributions of chemical compounds in exchange for shares of Signase, Inc., a Texas-based biotechnology company that researches cancer therapeutics. The transactions were recorded as an increase in investments in unconsolidated affiliates and sales of chemical compounds. Valuation of the shares received was consistent with recent equity placements of similar shares to other investors by Signase. The $500 sales value of the chemical compounds was consistent with average market values received in comparable transactions from other customers for similar volumes of compounds sold from our existing inventory.

Early in 2003, Signase advised its shareholders of its intent to seek additional financing at rates below those of the original investors. We determined this reduced level of market value to be "other than temporary" and as a result, wrote down our investment to approximate the then current offering price. Our total in-kind investment was $555 prior to the write-down of $405 in 2002, leaving a carrying value of $150. Tripos took a further write-down of the remainder of its investment in Signase, $150, as of March 31, 2003 after receiving information from Signase that attempts to raise capital were unsuccessful and that the company may be liquidated.

Since 2001, we have invested in the Life Science Ventures II fund administered by A.M. Pappas. This fund invests in new and developing companies in the life science sector. Our investment commitment of $2,500 represents approximately 2.2% of the total capital of the fund. As of March 31, 2004 we had invested $1,650 or 66% of our total commitment. The fund records investment impairments when identified, for which we recognize our pro-rata share of such impairments. In 2003, the fund's managers determined that certain investments were impaired. The Company recorded its pro-rata share of the fund's investment impairments, totaling $110, of which $51 was recorded in the first quarter of 2003.

The remainder of this report may contain certain statements that are forward-looking and involve risks and uncertainties. Words such as "expects", "anticipates", "projects", "estimates", "intends", "plans", "believes", variations of such words and similar expressions are intended to identify such forward looking statements. These statements are based on current expectations and projections made by management and are not guarantees of future performance. Therefore, actual events, outcomes and results may differ materially from what is expressed or forecast in such forward-looking statements. Among the factors that could cause actual results to differ materially from the forward-looking statements are set forth under the caption "Cautionary Statements -- Additional Important Factors to be Considered" in Item 7, Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") in Tripos' Form 10-K for 2003. Tripos undertakes no obligation to update any forward-looking statements in this Form 10-Q.

The following discussion should be read in conjunction with the audited consolidated financial statements and notes thereto.

Tripos provides products and services to the pharmaceutical, biotechnology, and life science industries to support early stage research activities. Tripos offerings are applied principally to assist research chemists to make decisions about the most productive new compounds to make and test as potential therapeutics. Through its own chemistry laboratories, Tripos can also make those compounds for its clients. Through strategic partnerships, Tripos can also test compounds for its clients.

The industries that Tripos serves are highly research driven. The mature pharmaceutical companies typically spend between 12% and 20% of their annual revenues on research in the search for new blockbuster drugs. Tripos' offerings are most relevant to the initial phase of drug discovery. Our products and services are designed and intended to provide our pharmaceutical and biotechnology customers with improved ways to identify and select the most promising drug candidates to take forward into the more expensive and time consuming stages of the drug development process. Depending on the number of compounds that a particular company has in different stages of their new therapeutic pipeline, they may reduce or increase investment in the other phases of research. Further, decisions by the pharmaceutical industry concerning their research investments are strongly influenced by decisions by the various governments of the world about drug pricing and regulation.

Tripos software products are sold on a renewable license basis, typically with term of one or three years. This business is generally predictable, with high renewal rates for licenses. Tripos management closely monitors license expirations and deploys sales staff to ensure the highest probability of renewals. Tripos service businesses, both informatics and chemistry, are much less predictable. The sales cycles for these offerings are typically long -- from six months to eighteen months -- and are highly influenced by factors in the macro-economic environment including the general state of the pharmaceutical industry and the political situations in various parts of the world. To forecast potential business in these areas, Tripos management strives to closely interact with the management of its customers and is closely involved in business development activities for service projects.

Large service contracts for pharmaceutical research, both informatics and chemistry, are complex and, because they are deployed in research applications where outcomes are uncertain, have a large risk component. Risk management in these projects begins with the definition of project requirements and continues through performance metrics and customer acceptance milestones. Due to the complexity of the projects and changing priorities within client organizations, it is typical that many decision points will arise that require management attention both at Tripos and at the client. To mitigate the project difficulties, Tripos has developed a process focus and management monitors milestones in the project plan according to the process workflow. Despite best efforts, however, some projects are of sufficient complexity that they present challenges that require revisions to the project plan and scope.

Having been a public company spinout in 1994 with limited capital, and limited additional capital raised over the past decade, the company has focused on profitability and cashflow. That said, the company has not always been profitable, but has achieved it in certain years. Major investments, say in the recent expansion of our chemistry research laboratories in England, have been funded by successful investments (i.e. Arena Pharmaceuticals), cash from operations, temporary use of debt capacity, and grant funding from the British government.

We license our discovery software products and post-contract support ("PCS") as either perpetual licenses or time-based licenses, typically one to three-year renewable contracts. The magnitude of these license fees is dependent on each customer's required usage levels, that is, the number of locations and individual users. Variations in licensing levels range from the low hundred-thousands up to several million dollars. The following are descriptions of our current sales models for discovery software:

Our integration of chemistry and biological data in the life sciences industries creates a revenue stream for enterprise software consulting. To serve this market, we maintain a staff of specialists who use our proprietary data integration framework, such as MetaLayer, Lithium, FormsBuilder, Tripos Electronic Notebook technologies, Registration Inventory & Ordering, and AUSPYX^TM to configure customized solutions for data management. Revenue may be generated on a billable rate per day, or upon achievement of milestones or deliverables and is recognized as production activities are performed. These contracts may also generate substantial license fee revenue for our proprietary software technologies. As with our discovery software products, licensing levels may range from the low hundred-thousands up to several million dollars.

We develop and manufacture general screening compound libraries for sale to the life sciences industry for a fee per compound delivered. This has created the opportunity to offer follow-up discovery research methods to customers for design and synthesis of focused libraries for lead optimization. We also market a comprehensive research process to our life sciences customers for rapid and cost effective discovery. This process combines advanced informatics, chemistry and biology products and services, and proprietary discovery technologies for efficient lead development, refinement, and optimization resulting in a tightly integrated process to facilitate synergies in drug discovery.

We also act as a reseller of computer hardware. Hardware sales are generally made to facilitate our software customers' access to hardware components and are not a primary focus of our sales activities. We act as an authorized reseller and order inventory on an "as needed" basis, and thus do not maintain any inventory. Accordingly, margins on these sales are relatively modest.

We generally expense research and development costs associated with software enhancements and new functionality. Thus, a significant portion of the costs associated with development and enhancement of software is accounted for as research and development and not as a cost of software sales. Certain software development projects require substantial commitments of time and resources. Costs of these projects are capitalized upon achievement of technological feasibility and/or a working model according to Statement of Financial Accounting Standards ("SFAS") No. 86.

Quarterly expenses include the costs of research and development for software development and new chemistry research. We believe that core selling and administrative costs will remain generally consistent as a percent of sales on an annual basis. Variability in quarterly expenses primarily occurs in relation to the level of revenues due to sales compensation, bonuses and staffing for selling, general and administrative functions and for periodic marketing activities such as appearances at trade exhibitions.

Our revenues and expenses vary from quarter to quarter depending upon, among other things, the timing of customers' budget processes, the success of our sales efforts, the lengthy sales cycle and our ability to influence customers and prospective customers to make decisions to outsource portions of their discovery process, the size of the customers' capital expenditure budgets, the ability to produce compound libraries in a timely manner, market acceptance of new products and enhanced versions of existing products, the timing of new product introductions by us and other vendors, changes in pricing policies (ours, partners and other vendors), consolidation in customer base, client involvement in decision points in contracts related to project plans, our ability to accurately match contract costs to milestone or contract performance requirements on our larger collaborative arrangements, and changes in general economic and competitive conditions. Because much of our software license and PCS r evenue along with our contracted discovery research revenue is recognized ratably over multiple periods, fluctuations in our quarterly revenues and earnings are caused principally by sales of compounds or by achievement of milestones on specific projects. Our management team monitors quarterly business activity with the aid of sales pipeline reports and monthly financial reports.

Net sales for the first quarter of 2004 were $15,460 compared to $13,686 in 2003, an increase of 13%. For the three months ended March 31, 2004, discovery software and support sales decreased 2% to $5,974 from $6,082 for same period in 2003. Discovery informatics services revenues for the first quarter declined 50% to $715. This decrease is due to reduced levels of active contracts while other projects progress toward milestones. Discovery research sales, including LeadQuest® compound libraries, accounted for $8,727 in the first quarter of 2004 and $6,085 in the same period in 2003, an increase of 43%. This increase in discovery research business was attributed to higher levels of production on the four-year, $90 million strategic compound design and synthesis contract with Pfizer. Hardware sales decreased by 52% to $44 for the first quarter 2004 from $91 in 2003. We do not actively market hardware products, but rather facilitate customer demand when required.

Net sales for the Company's activities outside of North America represented approximately 80% for the three-month period ending March 31, 2004 compared to 78% for the same period in 2003. North American net sales increased 4% for the quarter in 2004 compared to 2003. Net sales in Europe increased 23% for the first quarter of 2004, and accounted for 69% of total sales. This increase was principally related to progress on the Pfizer strategic compound design and synthesis project that was contracted through our European operations. Net sales in the Pacific Rim decreased by 45% for the first quarter of 2004 compared to the same period in 2003 driven primarily by fewer new limited-term time-based software license sales in first quarter 2004 while certain large limited-term contracts were renewed at their lower annual continuation fee amount. The Pacific Rim sales accounted for 4% and 9% of net sales for three-month periods in 2004 and 2003, respectively.

Cost of sales for the three-month period ending March 31, 2004 increased 34% to $7,693 compared to $5,732 for the same period in 2003. Cost of sales as a percent of net sales was 50% and 42% for the three-month periods in 2004 and 2003, respectively. Driving the increase in cost of sales was the increase in the mix toward higher cost discovery research products and services in relation to lower cost discovery software products and support. The cost of the discovery research business includes the raw material, direct labor and overhead costs to produce compound libraries and to deliver on contracted research projects. Discovery research contracts also include any third-party costs for production of larger quantities of intermediate or scale-up materials. The increase in cost of sales of discovery research activities in 2004 compared to 2003 is attributable to the continued ramp up in production for the Pfizer compound design and synthesis contract. Increased costs were most impacted by the required outsourcing to successfully deliver against the contract, combined with the financial impact of the decline of the US dollar against the Great Britain Pound Sterling where the operation is based.

Gross profit margin for the first quarter 2004 declined to 50% of total net sales versus 58% in the first quarter of 2003. A significant contribution to the decrease in overall gross margin was the shift in the mix of sales of high margin software products and support toward lower margin discovery research products and services. Included in the reduced gross profit from discovery research is a $613 currency impact, recorded in accounting for long-term contracts in which payments are received in the non-functional currency, on the Pfizer compound file enrichment project due to further weakening of the U.S. dollar against the British Pound Sterling. Portions of the contract proceeds were hedged, however the effects of hedging are reflected in "other income". We have also taken steps to mitigate some of our exposure on this contract through a recent amendment that provides for portions of the remaining project to be paid in Pounds Sterling. Gross profit for the company is also dependen t on costs of chemical materials and overhead, the mix of internal

versus third-party software product sales, foreign exchange rates and the company's ability to successfully deliver on informatics contracts.

Sales and marketing expenses decreased 3% to $3,142 for the first quarter of 2004 from $3,223 in the same period in 2003. Sales and marketing expenses as a percentage of net sales were 20% and 24% for the three-month periods in 2004 and 2003, respectively. The decrease in sales and marketing spending and their percent to net sales was attributable to lower salaries and commissions from open positions along with overall higher net sales.

Research and development expenses decreased by 5% to $2,828 from $2,985 and represented 18% and 22% of net sales for the three-month periods in 2004 and 2003, respectively. The decrease is attributable to reductions in permanent staff, reduced usage of contractors and improved efficiencies in applying R&D staff to discovery informatics projects (direct costs transferred to cost of sales) partially offset by production inefficiencies attributable to the move into our new UK laboratory facility.

General and administrative expenses decreased 8% to $1,879 from $2,036 for the first quarter of 2004 compared to 2003, and represent 12% and 15% of net sales for the respective periods. The decrease in expense for the first quarter is principally attributable to bad debt provisions recorded in the first quarter of 2003 of $265 for two biotech accounts and a loan to a former senior executive.

Other income decreased 96% to $42 for the first quarter in 2004 from $937 in the same period in 2003. In 2004, we sold our last 31 shares of Arena Pharmaceuticals Inc. to generate a gain of $143 while in the first quarter of 2003, we sold 273 shares of Arena resulting in a gain of $1,309. For 2004, net of interest income, interest expense, currency and other adjustments was expense of $101 compared to $171 in 2003. Additionally, we wrote-down two investments totaling $201 (see Note 9, Long-term Investments) in the first quarter of 2003.

Income tax benefit was $15 for the first quarter of 2004 compared to a $277 income tax expense for the same period in 2003, which represent an effective tax rate of 38% and 43%, respectively. The 38% effective tax rate for 2004 reflects management's current estimate of the distribution of earnings among the statutory jurisdictions in which we operate and the valuation of certain tax credits and net operating losses in the U.S. and U.K. for the tax year ending December 31, 2004. We have established a valuation allowance against deferred tax assets created primarily by prior net operating losses. This may result in a lower effective tax rate in future periods upon the recognition of income in the jurisdictions where the deferred tax assets were created. The establishment of the valuation allowance for the deferred tax assets does not impair our ability to use the deferred tax assets upon achieving profitability.

Net cash provided by operations in 2004 was $9,142. Sources of operating funds for 2004 were net collections of accounts receivable of $4,677, reductions in prepaid expenses of $1,221, increased deferred revenue of $4,472 plus the add-back of non-cash depreciation and amortization expenses of a combined $677 and a net reduction in the amount of foreign currency forward contracts outstanding of $757. Operating funds used in 2004 were from a net loss of $25, changes in net deferred tax position of $243, reductions of accounts payable & accrued expenses of $2,251, less the pre-tax gain of $144 from the sale of shares of Arena Pharmaceuticals common stock. In the first quarter of 2003, cash from operations was $5,095. Last year, $8,372 was generated by the net collection of accounts receivable, net income of $370 plus the combined add-back of depreciation and amortization of $1,052. Cash used in operations in the first quarter

of 2003 included increased inventory of $715, increased prepaid expenses of $848 along with decreases in deferred taxes of $296, accounts payable and accrued expenses of $683, and deferred revenue of $848 less the gain on the sale of Arena shares included in net income of $1,309. The principal differences in cashflow from operations, year over year, are related to changes in net income, slowing of the growth in inventory produced for our compound contract with Pfizer and the 2004 increase in deferred revenue from the receipt of advance funding of technology access fees.

Cash used in investing activities in 2004 was $1,093 generated principally from the acquisitions of capital expenditures of $1,101, investment in the A.M. Pappas Life Science Ventures II of $188 partially offset by the proceeds from the sale of Arena shares of $196. Cash used in investing activities during 2003 were for property and equipment acquisitions of $2,404 and capitalized development costs for our ChemCoreÔ technology of $306. These were partially offset by the combined write-down of our investments in Signase, Inc. and the A.M. Pappas Life Science Ventures II fund of $201 and the $1,770 of gross proceeds from the sale of Arena shares. As of March 31, 2004, we no longer held shares in Arena Pharmaceuticals. In the first quarter of 2004 we moved into our expanded chemistry laboratory facility. During 2004 we expect to fund $7,000 for capital expenditure that include the balance of the payments to the general contractor for the building along with th e equipment required to fulfill our contracted business. Additionally, over the next 12 to 18 months, we will be required to fund the remainder of our investment commitment ($812) to the Life Science II Investment Fund.

For the first three-month period in 2004, the net cash used in financing activities was $4,087, consisting of payments on bank loans and capital lease arrangements totaling $4,445, less proceeds from additional capital leases of $341 and the issuance of shares under our employee stock plans of $17. For the same period in 2003, $3,091 of cash used in financing activities was for the reduction of outstanding debt.

Subsequent to March 31, 2004, the company and LaSalle Bank executed an amendment to the existing credit facility. The modified revolving credit facility, which remains at $6,000, is a one-year commitment with two covenants (interest coverage and minimum shareholders' equity), a clean-down provision and a 25 basis point increase in associated fees. The maturity date on the mortgage loan remains unchanged (December 2005). The amended line of credit portion of the facility more appropriately addresses the Company's reduced requirement to fund capital expenditures through bank debt while meeting the expected working capital funding needs over the next twelve months. At March 31, 2004, we had borrowings outstanding of $4,500 on the line of credit that were included in short-term debt.

Early in April 2004, we secured additional capital lease financing of approximately $1,500 to fund a portion of our remaining 2004 capital expenditure requirements for the laboratory. The remainder of operating needs and capital expenditures are expected to be funded through operations. We have made reductions in staff in the first quarter of 2004 along with continued controls on spending to help achieve this goal. Activities over and above normal operations may require additional sources of funding that are not presently identified. However, we believe that with our cash, accounts receivable balances, projected cash flows from operations, access to available borrowings from LaSalle Bank, if any, and incremental capital leases, we will be able to meet our liquidity needs and capital expenditure requirements for at least the next twelve months. We expect that our capital expenditure requirements will drop substantially upon completion of the funding of the chemistry laboratory expansion. As a result, the current need for external funding will be reduced in future periods.

Due to the capital needs inherent to our business and despite current capital markets uncertainties, we may decide to seek additional financing to support our objectives to enhance product development, expand

existing markets and enter new markets, expand our chemistry research laboratories, fund participation in new therapeutic collaborations, or enhance our capital base for other purposes. In making decisions regarding access to additional capital, we will consider the availability and terms of financing alternatives, as well as our objective to maintain financial flexibility to support planned and opportunistic growth of our business. Additional capital may be in the form of equity or debt securities, and may be raised in public offering or private placement transactions. See "Management's Discussion and Analysis of Financial Condition and Results of Operations - Liquidity and Capital Resources", "Cautionary Statements - Additional Important Factors to be Considered" and Note 12 of the Notes to Consolidated Financial Statements in our Annual Report on Form 10-K for the year ended December 31, 2003 for a discussion of the credit facilities available to us.

Periodic reports on Form 10-Q, Form 10-K and other filings with the Securities and Exchange Commission ("SEC") on Form 8-K and S-8, can be found on the Tripos web site at www.tripos.com under the heading Investor Relations - SEC Filings.

(a)   The Company's Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of the Company's disclosure controls and procedures (as defined under Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this report. Based upon that evaluation, the Company's Chief Executive Officer and Chief Financial Officer have concluded that the Company's disclosure controls and procedures are adequate and effective.

(b)   During the quarterly period covered by this report, there were no changes in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Item 1.     Legal Proceedings

On or about July 24, 2003, the Company and two of its executive officers, Dr. John P. McAlister and Mr. B. James Rubin, were sued in federal district court in St. Louis, Missouri on behalf of purchasers of the Company's common stock during the first half of 2002. The class action suit, Mr. David Montalvo, et.al. as lead plaintiffs, alleges that statements made by the Company in press releases and other public disclosures contained materially false and misleading information in violation of the federal securities laws. The plaintiffs have informed the Company of their intent to amend their complaint to add additional allegations. The amount of damages being sought is unspecified at this time. Although the Company believes that it has meritorious defenses to the claims alleged against it in this action, it is too early in the litigation to provide an accurate assessment of the likelihood or the extent of any liability arising from this matter.

Item 2.     Changes in Securities

          None

 Item 3.     Defaults upon Senior Securities

          None

Item 4.     Submission of Matters to a Vote of Security Holders

Item 5.     Other Information

          None

Item 6.     Exhibits and Reports on Form 8-K

          (a) List of Exhibits

          (b) The Company filed the following reports on Form 8-K during the period from January 1, 2004 to March 31, 2004:

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

1. Effective Date. *

2. Definitions and Rules of Construction. *

3. Lender's Commitment. *

4. Interest. *

5. Fees. *

6. Payments. *

7. Procedure for Obtaining Advances and Letters of Credit. *

8. Security and Guaranties. *

9. Power of Attorney. *

10. Conditions of Lending. *

11. Additional Conditions to Issuance of Letters of Credit. *

12. Representations and Warranties. *

13. Survival *

14. Affirmative Covenants *

15. Negative Covenants *

16. Financial Covenants. *

17. Default. *

18. Changes in Circumstances. *

19. Taxes. *

20. Usury Limitations. *

21. General. *

22. Miscellaneous. *

THIS AMENDED AND RESTATED LOAN AGREEMENT, dated as of December 2, 2002 (this "Agreement"), is made among TRIPOS, INC., a Utah corporation ("Borrower"), TRIPOS REALTY, LLC, a Missouri limited liability company ("Tripos Realty" or "Guarantor") and LASALLE BANK NATIONAL ASSOCIATION (f/k/a LaSalle National Bank, the "Lender").

Recitals

A. Borrower, Tripos Realty and Lender entered into a Loan Agreement dated as of April 30, 1999 (as amended to date, the "Prior Loan Agreement"), pursuant to which the Borrower and Tripos Realty executed and delivered a Term Note B dated April 30, 1999 (the "Prior Term Loan Note"), Borrower executed and delivered an Amended and Restated Revolving Note dated June 30, 1999 (the "Prior Revolving Note", and together with the Prior Term Loan Note, the "Existing Prior Notes"), and Borrower executed and delivered Term Note A dated April 30, 1999 (which note has been paid in full and cancelled).

B. The parties hereto wish to amend and restate the Prior Loan Agreement in its entirety and amend certain of the provisions thereof, it being the intention of the parties hereto that the loans outstanding under the Prior Loan Agreement and the Existing Prior Notes on the Amended and Restated Effective Date (as hereinafter defined) shall continue and remain outstanding and not be repaid on the Amended and Restated Effective Date.

C. The Borrower and Tripos Realty have requested Lender to increase the amount and extend the term of the existing term loan, Borrower has requested Lender to increase the amount and extend the term of the existing revolving loan facility, to issue a letter of credit to support a loan to be made to Tripos Receptor Research Limited (a wholly owned foreign subsidiary of Borrower), and to make certain other changes to the Prior Loan Agreement, and Lender is willing to agree to such requests, subject to the terms and conditions hereinafter set forth.

In consideration of the mutual agreements herein and other sufficient consideration, the receipt of which is hereby acknowledged, the parties hereto hereby agree that the Prior Loan Agreement shall, as of the Amended and Restated Effective Date, be amended and restated in its entirety as follows:

Effective Date.

This Agreement is effective April 30, 1999, as amended and restated as of December 2, 2002.

Definitions and Rules of Construction.

Listed Definitions.

Capitalized words defined in the Glossary and Index of Defined Terms attached hereto as Exhibit 2.1 shall have such defined meanings wherever used in this Agreement and the other Loan Documents.

Other Definitions.

If a capitalized word in this Agreement is not defined in the Glossary and Index of Defined Terms, it shall have such meaning as defined elsewhere herein, or if not defined elsewhere herein, the meaning defined in the UCC.

References to Borrower.

The word "Borrower" refers to Tripos, Inc., a Utah corporation.

References to Covered Persons.

The words "Covered Person," "a Covered Person," "any Covered Person," "each Covered Person," and "every Covered Person" refer to Borrower and each of its direct and indirect Subsidiaries separately, including, without limitation, Tripos Realty, Tripos UK Holdings Limited, Tripos UK Limited, Tripos Receptor Research Limited, Tripos SARL, and Tripos GmbH. The words "Covered Persons" refer to Borrower and its Subsidiaries collectively.

Accounting Terms.

Unless the context otherwise requires, accounting terms herein that are not defined herein shall be determined under GAAP. All financial measurements contemplated hereunder respecting Borrower shall be made and calculated for Borrower and all of its now existing or later acquired, created or organized subsidiaries, on a consolidated basis in accordance with GAAP unless expressly provided otherwise herein.

Meaning of Satisfactory.

Whenever herein a document or matter is required to be satisfactory to Lender, unless expressly stated otherwise, such document must be satisfactory to Lender in both form and substance in its commercially reasonable discretion, and unless expressly stated otherwise, Lender shall have the commercially reasonable discretion to determine whether the document or matter is satisfactory. The right to exercise such discretion is absolute.

Computation of Time Periods.

In computing or defining periods of time from a specified date to a later specified date, and in computing the accrual of interest or fees, the words from shall mean from and including and the words to and until shall each mean to but excluding. Periods of days referred to in this Agreement shall be counted in calendar days unless Business Days are expressly prescribed, and references in this Agreement to months and years are to calendar months and calendar years unless otherwise specified.

General.

Unless the context of this Agreement clearly requires otherwise: (i) references to the plural include the singular and vice versa; (ii) references to any Person include such Person's successors and assigns but, if applicable, only if such successors and assigns are permitted by this Agreement; (iii) references to one gender include all genders; (iv) including is not limiting; (v) or has the inclusive meaning represented by the phrase and/or; (vi) the words hereof, herein, hereby, hereunder and similar terms in this Agreement refer to this Agreement as a whole, including its Exhibits, and not to any particular provision of this Agreement; (vii) the word Section or section and Page or page refer to a section or page, respectively, of, and the word Exhibit refers to an Exhibit to, this Agreement unless it expressly refers to something else; (viii) reference to any agreement, document, or instrument (including this Agreement and any other Loan Document or other agreemen t, document or instrument defined herein), means such agreement, document, or instrument as amended, modified, restated or replaced and in effect from time to time in accordance with the terms thereof and, if applicable, the terms hereof, and includes all attachments thereto and, if applicable, the terms hereof, and includes all attachments thereto and documents incorporated therein, if any; and (ix) general and specific references to any Law means such Law as amended, modified, codified or reenacted, in whole or in part, and in effect from time to time. Section captions and the Table of Contents are for convenience only and shall not affect the interpretation or construction of this Agreement or the other Loan Documents.

Lender's Commitment.

Subject to the terms and conditions hereof, and in reliance upon the representations and warranties of Borrower herein, and the representations and warranties of Guarantors in their Guaranty, Lender makes the following commitment to Borrower:

Revolving Loan Commitment.

Aggregate Amount; Reductions.

Limitation on Revolving Loan Advances.

Revolving Note.

General Letter of Credit Commitment.

On the Amended and Restated Effective Date, Lender shall issue commercial and standby letters of credit (each a "Letter of Credit") for the account of Borrower from time to time from the Amended and Restated Effective Date to the Revolving Loan Maturity Date (the "Letter of Credit Commitment"), but only in connection with transactions satisfactory to Lender and only if the Letter of Credit Exposure will not as a result of such issuance exceed the lesser of (i) $2,000,000 and (ii) any excess of the Maximum Available Amount over the then outstanding Revolving Loans. The expiration date of any Letter of Credit will not be more than one year after its issuance date and in no event will be later than the Revolving Loan Maturity Date unless Borrower deposits with Lender cash collateral satisfactory to Lender to secure reimbursement by Borrower of all amounts drawn on such Letter of Credit and all applicable fees.

Construction Letter of Credit Commitment.

In addition to the Letters of Credit described under Section 3.2, subject to the satisfaction of the conditions set forth in Section 11.7 to Lender's satisfaction in its sole discretion, Lender commits to issue the Construction Letter of Credit for the account of Borrower on the UK Effective Date, if, and only if, Borrower deposits with Lender cash collateral and/or marketable securities satisfactory to Lender in an amount equal to the maximum aggregate amount of the Construction Letter of Credit (the "Cash Collateral Requirement") to secure reimbursement of Lender by Borrower of all amounts drawn on such Construction Letter of Credit and all applicable fees related thereto or associated therewith (the "Construction Letter of Credit Commitment"). Any such cash collateral shall be held in a restricted account with Lender or ABN Amro London (the "Restricted Account") and any marketable securities shall be held in a brokerage account with Lender, which account shall be pledged to Lender (the "Brokerage Account"). In determining Borrower's continuing compliance with the Cash Collateral Requirement, marketable securities deposited in the Brokerage Account shall be valued at 70% of from time to time fair market value. Upon demand by Lender, Borrower shall immediately replenish the Restricted Account and the Brokerage Account, as the case may be, in order to at all times maintain compliance with the Cash Collateral Requirement. The Cash Collateral Requirement shall cease if (i) there is no Default or Event of Default, and (ii) Borrower's EBITDA, calculated for December 31, 2003 for the preceding twelve (12) month period, is equal to, or exceeds, $2,950,000. The expiration date of the Construction Letter of Credit will not be more than three years after the Amended and Restated Effective Date and in no event later than the Revolving Loan Maturity Date unless Borrower or a Covered Person deposits with Lender cash collateral satisfactory to Lender to secure reimbursement by Borrower of all amounts drawn on such Construction Letter of Credit and all applicable fees.

Term Loan Commitment.

Amount.

Repayment of Term Loan.

Term Note.

Interest.

Interest on Letters of Credit.

Borrower shall pay interest on the unreimbursed amount of each draw on a Letter of Credit (other than the Construction Letter of Credit) at a rate per annum equal to the Prime Rate.

Interest on Draws on Construction Letter of Credit.

Borrower shall pay interest on the unreimbursed amount of the Construction Letter of Credit at a rate per annum equal to the Prime Rate plus 2.00%.

Interest on the Term Loan.

Borrower shall pay interest on the Term Loan at a rate of interest in an amount equal to two and twenty five one hundredths of one percent (2.25%) above the from time to time Eurodollar Rate for 90 day Interest Periods, as determined two days before the first day of each calendar quarter during the term of the Term Loan.

Interest on Revolving Loans; Interest Periods for Eurodollar Loans.

Borrower may, as provided herein, designate any Revolving Loan or part of any such Loan to be either a Prime Rate Loan or a Eurodollar Loan; provided, however, during the existence of an Existing Default, Borrower may not designate a Loan or any part of any such Loan as a Eurodollar Loan. Each Prime Rate Loan when made will bear interest at the Prime Rate (which will fluctuate as described in Section 4.8) plus the Prime Increment (determined from time to time as provided in Section 4.5). Each Eurodollar Loan when made will bear interest at the Adjusted Eurodollar Rate. The "Adjusted Eurodollar Rate" for any Eurodollar Loan is the Eurodollar Rate (which shall be determined before the beginning of the applicable Interest Period as provided herein and shall apply throughout such Interest Period) plus the applicable Eurodollar Increment (as defined below) determined from time to time as provided in Section 4.5. Except for the Term Loan, Borrower may also, as provided he rein, convert some or all of a Prime Rate Loan into a Eurodollar Loan, and some or all of a Eurodollar Loan into a Prime Rate Loan. Borrower shall select an Interest Period for each Eurodollar Loan. Subject to the foregoing, each Interest Period shall be either thirty (30), sixty (60) or ninety (90) days; provided that (i) every such Interest Period shall commence on the date of the Advance; (ii) if any Interest Period would otherwise expire on a day of a calendar month which is not a Business Day, then such Interest Period shall expire on the next succeeding Business Day in that calendar month; provided, however, that if the next succeeding Business Day would be in the following calendar month, it shall expire on the first preceding Business Day; (iii) any Interest Period that begins on the last Business Day of a calendar month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of a calendar month; and (iv) no Interest Period shall extend beyond the Revolving Loan Maturity Date.

Increments.

The Prime Increment shall equal zero percent (0%) and the Eurodollar Increment shall equal two and seventy five one hundredths percent (2.75%)

Conversion of Loans.

Except with regard to the Term Loan, Borrower may (i) at any time convert some or all of a Prime Rate Loan to a Eurodollar Loan, or (ii) at the end of any Interest Period of a Eurodollar Loan, continue such Loan as a Eurodollar Loan for an additional Interest Period or convert some or all of such Eurodollar Loan to a Prime Rate Loan. To cause any such conversion or continuation, Borrower shall give Lender, prior to 11:00 a.m. St. Louis time at least two Business Days prior to the date the conversion or continuation is to be effective, a written request (which may be mailed, personally delivered or telecopied as provided in Section 22.1) or an oral request (which must be confirmed by facsimile on such date) (a) specifying whether a conversion or continuation is requested, (b) in the case of a conversion, specifying the amount to be converted and whether it is to be a Eurodollar Loan or a Prime Rate Loan upon the conversion, and (c) in the case of any conversion to or co ntinuation of a Eurodollar Loan, specifying the Interest Period therefor. If such notice is not given by 11:00 a.m. St. Louis time on the second Business Day preceding the last day of the Interest Period of a Eurodollar Loan, then Borrower shall be deemed to have timely given a notice to Lender requesting to convert all of such Eurodollar Loan to a Prime Rate Loan. In the case of a Eurodollar Loan, any conversion or continuation shall become effective only on the day following the last day of the current Interest Period.

Time of Accrual.

Interest shall accrue on all principal amounts outstanding from the date when first outstanding to the date when no longer outstanding. Amounts shall be deemed outstanding until payments are applied thereto as provided herein.

Computation.

Interest shall be computed for the actual days elapsed over a year deemed to consist of 360 days. Interest rates that are based on the Prime Rate shall change simultaneously with any change in the Prime Rate and shall be effective for the entire day on which such change becomes effective. The Prime Rate will be determined by Lender before the initial Advance on the Amended and Restated Effective Date and on each Business Day thereafter when the Prime Rate changes.

Rate After Maturity.

Borrower shall pay interest on the Loans after their Maturity, and (at the option of Lender on the Loans and on the other Loan Obligations) upon the occurrence and during the continuance of an Event of Default, at a rate per annum of three percent (3%) plus the interest rate otherwise in effect hereunder. Notwithstanding the foregoing, with respect to Loan Obligations arising from the Construction Letter of Credit, at Lender's option, Borrower shall pay interest on draws on the Construction Letter of Credit upon the occurrence and during the continuance of an Event of Default, at a rate per annum not to exceed the Prime Rate plus three percent (3%).

Rate After Failure to Timely Deliver Financial Statements.

Notwithstanding anything set forth herein to the contrary, if Borrower fails to timely deliver Financial Statements as required by Section 14 hereof, the rate of interest, effective as of the date such Financial Statements were to have been delivered, shall be the greater of, the Prime Rate and the Eurodollar Rate, which Eurodollar Rate shall be calculated using a Eurodollar Increment equal to two and seventy five one hundredths of one percent (2.75%).

Fees.

Closing Fee.

Borrower shall pay to Lender a "Closing Fee" equal to Twenty Five Thousand Eight Hundred Seventy Five Dollars ($25,875) on the Amended and Restated Effective Date. Once received by Lender, the Closing Fee shall not be refundable to Borrower for any reason.

Unused Line Fee.

In consideration of the Revolving Loan Commitment, Borrower agrees to pay Lender a fee (the "Unused Line Fee") on the Revolving Loan Commitment less the aggregate amount of outstanding Revolving Loans and LOC Obligations for each day during the applicable Unused Line Fee Calculation Period (as hereinafter defined) at a rate per annum equal to three hundred seventy five one thousandths of one percent (.375%) times the unused portion of the Revolving Loan Commitment. The Unused Line Fee shall commence to accrue on the Amended and Restated Effective Date and shall be due and payable in arrears on the first Business Day of each calendar quarter for the immediately preceding quarter (or portion thereof) (each such quarter or portion thereof for which the Unused Line Fee is payable hereunder being herein referred to as the "Unused Line Fee Calculation Period"), beginning with the first of such dates to occur after the Closing Date.

Letter of Credit Fees.

Borrower shall pay to Lender a "Letter of Credit Fee" for each Letter of Credit issued by Lender (other than the Construction Letter of Credit), which shall be calculated by applying the daily equivalent of the per annum Eurodollar Increment in effect on the date of issuance of such Letter of Credit to the undrawn amount available under such Letter of Credit as of each day commencing when such Letter of Credit is issued by Lender. The Letter of Credit Fee for each documentary Letter of Credit shall be determined in accordance with Lender's published letter of credit fee schedule for documentary letters of credit. The Letter of Credit Fee due for any Letter of Credit shall be payable quarterly in arrears beginning on the first day of the first calendar quarter after the date such Letter of Credit is issued and continuing on the first day of each calendar quarter thereafter while such Letter of Credit is outstanding.

Construction Letter of Credit Fees.

Borrower shall pay to Lender a "Construction Letter of Credit Fee", which shall be calculated by applying the daily equivalent of twenty five one hundredths of one percent (.25%) per annum of the undrawn amount available under the Construction Letter of Credit, as of each day commencing when such Construction Letter of Credit is issued by Lender and adjusted as the issued and available amount of the Construction Letter of Credit is increased. The Construction Letter of Credit Fee shall be payable quarterly in arrears beginning on the first day of the first calendar quarter after the date such Construction Letter of Credit is issued, and continuing on the first day of each calendar quarter thereafter while such Construction Letter of Credit is outstanding.

Calculation of Fees.

All of the foregoing fees and all other fees payable to Lender that are based on an annual percentage shall be calculated on the basis of a year deemed to consist of 360 days and for the actual number of days elapsed, and in accordance with Section 2.7.

Payments.

Scheduled Payments on Revolving Loan.

Interest.

Principal.

RESERVED.

Scheduled Payments on Term Loan.

Commencing January 1, 2003, Borrower and Tripos Realty shall pay quarterly installments of principal in the amount of Fifty Four Thousand Three Hundred Seventy Five Dollars ($54,375.00), plus accrued interest, on the first day of each calendar quarter, and shall make a final payment of the outstanding principal, plus accrued interest, on the Term Loan Maturity Date.

Reimbursement Obligations.

Borrower hereby unconditionally agrees to immediately pay to Lender on demand at the Lending Office all amounts required to pay all drafts drawn under the Construction Letter of Credit and all other Letters of Credit issued for the account of Borrower and all reasonable expenses incurred by Lender in connection with such Letters of Credit and, in any event and without demand, to remit to Lender (which may be through obtaining Advances if permitted under Section 3.1.2) sufficient funds to pay all Obligations arising under any Letter of Credit issued for the account of Borrower. Borrower agrees to comply with all provisions of any Letter of Credit application and reimbursement agreement, and each application and reimbursement agreement shall be deemed to be a "Loan Document" hereunder.

Prepayments.

Revolving Loan Mandatory Prepayments When Over-Advances Exist.

Manner of Payments and Timing of Application of Payments.

Payment Requirement.

Application of Payments and Proceeds.

All payments received by Lender in immediately available funds at or before 1:00 p.m. (St. Louis time) on a Business Day will be applied to the relevant Loan Obligation on the same day. Such payments received on a day that is not a Business Day or after 1:00 p.m. on a Business Day will be applied to the relevant Loan Obligation on the next Business Day. Except as expressly provided otherwise herein, Lender may apply, and reverse and reapply, payments and proceeds of the Collateral to the Loan Obligations in such order and manner as Lender determines in its absolute discretion absent specific instructions by Borrower. Borrower hereby irrevocably waives the right to direct the application of payments and proceeds of Collateral so long as there is any Existing Default. All payments and prepayments shall be deemed made on Prime Rate Loans that are included in the Revolving Loans, and then to the Eurodollar Loans included in the Revolving Loans; provided, however, that payments received on the last day of any Interest Period shall first be applied to the Eurodollar Loans with an Interest Period ending on such date until such Loans are paid in full, and then to the Prime Rate Loans included in the Revolving Loan. Any payments received pursuant to Section 15.1 with respect to the Term Loan shall be applied in inverse order of Maturity.

Interest Calculation.

Returned Instruments.

If a payment is made by check, draft or other instrument and the check, draft or other instrument is returned unpaid, any application of the payment to the Loan Obligations will be reversed and will be treated as never having been made.

Compelled Return of Payments or Proceeds.

If Lender is for any reason compelled to surrender any payment or any proceeds of Collateral because such payment or the application of such proceeds is for any reason invalidated, declared fraudulent, set aside, or determined to be void or voidable as a preference, an impermissible setoff, or a diversion of trust funds, then this Agreement and the Loan Obligations to which such payment or proceeds was applied or intended to be applied shall be revived as if such application was never made; and Borrower shall be liable to pay to Lender, and shall indemnify Lender for and hold Lender harmless from any loss with respect to, the amount of such payment or proceeds surrendered. This Section shall be effective notwithstanding any contrary action that Lender may take in reliance upon its receipt of any such payment or proceeds. Any such contrary action so taken by Lender shall be without prejudice to Lender's rights under this Agreement and shall be deemed to have been conditioned upon the application of such pa yment or proceeds having become final and indefeasible. The provisions of this Section shall survive termination of the Commitments, the expiration of all Letters of Credit, and the payment and satisfaction of all of the Loan Obligations.

Due Dates Not on Business Days.

If any payment required hereunder becomes due on a date that is not a Business Day, then such due date shall be deemed automatically extended to the next Business Day.

Accrued Fees and Interest.

The quarterly fees and interest accrued and unpaid under the Prior Loan Agreement as of the Amended and Restated Effective Date for the partial calendar quarterly period from October 1, 2002 to the Amended and Restated Effective Date shall be payable on January 1, 2003 together with the quarterly fees and interest accruing under this Agreement from the Amended and Restated Effective Date for the balance of the calendar quarterly period. In the case of Eurodollar Loans outstanding on the Amended and Restated Effective Date, the interest accrued shall be paid at the end of the applicable Interest Period.

Procedure for Obtaining Advances and Letters of Credit.

Initial Advances.

Lender will fund the increase in the Term Loan and make the initial Revolving Loan Advance, if any, on the Amended and Restated Effective Date as directed by Borrower in a written direction delivered to Lender. The manner of disbursement shall be subject to Lender's approval.

Borrowing Base Certificates.

On the Amended and Restated Effective Date if Borrower desires a Revolving Loan Advance, and on the 15th day of each month thereafter and upon each request of Lender, Borrower shall deliver (a) an aging of all Accounts, and (b) a Borrowing Base Certificate to Lender in the form of Exhibit 7.2 attached hereto, reflecting the Accounts at the end of the preceding calendar month, together with such supporting information as Lender may require from time to time.

Revolving Loan Advances.

Borrower Requests.

Lender's Right to Make Other Revolving Loan Advances.

Payments to Other Creditors.

Letters of Credit.

Borrower may request the issuance of the Construction Letter of Credit or a Letter of Credit by submitting an issuance request to Lender that meets the requirements of Section 7.10 and executing the reimbursement agreement required under Section 11.1 or Section 11.7.3, as applicable, no less than five Business Days prior to the requested issue date for the Construction Letter of Credit or any other Letter of Credit.

Disbursement.

Provided that all conditions precedent herein to a requested Advance have been satisfied, Lender will make the amount of such requested Advance available to Borrower on the applicable Advance Date in immediately available funds in Dollars at the Lending Office.

Restrictions on Advances.

No Prime Rate Advance will be made unless it is a whole multiple of $1,000.00 and not less than $10,000.00. No Eurodollar Advance will be made unless it is a whole multiple of $50,000.00 and not less than $100,000.00. No more than one Revolving Loan Advance (which may include a portion which is a Eurodollar Loan and a portion which is a Prime Rate Loan) will be made on any one day pursuant to a request for a Revolving Loan Advance although a second Revolving Loan Advance on a given day may be made for a Prime Rate Loan pursuant to a request for a Revolving Loan Advance that was made on a different day than the other request. Advances will only be made for the purposes permitted in Section 14.1.

Restriction on Number of Eurodollar Loans.

No more than seven (7) Eurodollar Loans may be outstanding at any one time.

Each Advance Request Certification.

Each submittal of a request for an Advance by a Borrowing Officer shall constitute a certification by Borrower that (i) there is no Existing Default, (ii) all representations and warranties of Borrower in this Agreement and the other Loan Documents are then true, with such exceptions as have been disclosed to Lender in writing by Borrower as addenda to the Disclosure Schedule which are satisfactory to Lender, and will be true on the Advance Date or issuance date, as applicable, as if then made with such exceptions and except that with respect to the representations and warranties made regarding Financial Statements or financial data, such representations and warranties shall be deemed made with respect to the most recent Financial Statements and other financial data delivered by Borrower, (iii) the amount of the requested Revolving Loan Advance will not, when added to the current amount of the aggregate Revolving Loans, exceed the Maximum Available Amount and (iv) all conditions precedent hereunder to the making of the requested Advance shall have been satisfied.

Requirements for Every Advance Request.

Only a request (which shall be in writing and mailed, personally delivered or telecopied as provided in Section 22.1; or if oral, which shall be confirmed in writing via facsimile on the date of such request) in the form of Exhibit 7.9 from a Borrowing Officer to Lender that specifies the amount of the Advance to be made, the Advance Date for the requested Advance, the portion of the Advance which is requested to be a Eurodollar Advance, the portion of the Advance which is requested to be a Prime Rate Advance, and the Interest Period to be applicable to the Eurodollar Loan that will result from a requested Eurodollar Advance, shall be treated as a request for an Advance. No Advance Date for any requested Advance may be other than a Business Day. A request for a Eurodollar Advance must be given prior to 11:00 a.m., St. Louis time, at least two Business Days prior to the Advance Date for such Eurodollar Advance. A request for a Prime Rate Advance must be given prior to 11:00 a.m ., St. Louis time, on the Advance Date for such Prime Rate Advance.

Requirements for Every Request for Issuance of a Letter of Credit.

Only a written request from a Borrowing Officer to Lender that specifies the amount, the requested issue date and the beneficiary of the requested Letter of Credit and other information necessary for its issuance shall be treated as an issuance request for the purposes hereof.

Exoneration of Lender.

Lender shall not incur any liability to Borrower for treating a request that meets the express requirements of Section 7.9 or Section 7.10, as applicable, as a request for an Advance or a request for issuance of a Letter of Credit, if Lender believes in good faith that the Person making the request is a Borrowing Officer. Lender shall not incur any liability to Borrower for failing to treat any such request as a request for an Advance or a request for issuance of a Letter of Credit, as applicable, if Lender believes in good faith that the Person making the request is not a Borrowing Officer.

Suspension of Obligation to Make Eurodollar Advances.

If (i) on any date for determining the Eurodollar Rate for any Interest Period, by reason of any changes arising after the Amended and Restated Effective Date affecting the London Interbank Market or Lender's position in such market, adequate and fair means do not exist for ascertaining the applicable interest rate on the basis provided for in the definition herein of Eurodollar Rate, or (ii) the making of any Advance which is to be a Eurodollar Advance or the continuance by Lender of any Eurodollar Loan has become unlawful by compliance by Lender in good faith with any Law or any pronouncement of a Governmental Authority (whether or not having the force of law and whether or not failure to comply therewith would be unlawful), then Lender shall promptly give notice to Borrower of such determination. Until Lender notifies Borrower that the circumstances giving rise to the suspension described herein no longer exist, (a) the obligation of Lender to fund Eurodollar Advances shall be suspended, (b) each outst anding Eurodollar Loan shall be automatically converted into a Prime Rate Loan, on the earlier of the last day of the Interest Period for such Eurodollar Loan or the last date permitted by applicable Law, and (c) all Revolving Loan Advances shall be Prime Rate Advances. Notwithstanding anything to the contrary contained herein, if any part of a Eurodollar Loan is converted to a Prime Rate Loan pursuant to this Section 7.12, the per annum interest rate applicable thereto from and after the effective date of such conversion shall be the Prime Rate (but otherwise calculated as provided in Section 4).

Security and Guaranties.

Lender may, either before or after an Event of Default, exchange, waive or release the Security Interests in any of the Collateral, or in Lender's absolute discretion permit Borrower to substitute any real or personal property for any of the Collateral, without affecting the Loan Obligations or Lender's right to take any other action with respect to any other Collateral. Upon indefeasible payment in full in cash of the Loan Obligations and the termination of the Commitments, Lender shall, upon the request of Borrower, and at Borrower's sole cost and expense, provide documentation satisfactory to Borrower that Lender has released all mortgages, security agreements, UCC financing statements, collateral assignments, pledge agreements, and guaranties.

To secure the payment and performance of the Loan Obligations, Borrower shall, except as expressly set forth hereinbelow to the contrary, on the Amended and Restated Effective Date, execute and deliver, or cause to be executed and delivered, to Lender the following documents from time to time, each satisfactory to Lender:

Deed of Trust Modification; Mortgage.

On the UK Effective Date, the LaSalle UK Mortgage, satisfactory to Lender, and, on the Amended and Restated Effective Date, a Modification to Deed of Trust executed and delivered to Lender by Tripos Realty ("Deed of Trust Modification"), satisfactory to Lender and if any tenants have possession of a material portion of the Mortgaged Property, Borrower shall also deliver or cause to be delivered to Lender a nondisturbance, attornment, and subordination agreement or an estoppel certificate, as elected by Lender in its discretion, executed by such tenant and acceptable to Lender.

Security Agreements.

Except as otherwise expressly agreed herein or in the Security Documents, security agreements from Borrower and Tripos Realty satisfactory to Lender and granting to Lender a Security Interest under the UCC in all of the Goods, Equipment, Accounts, Inventory, Instruments, Documents, Chattel Paper, General Intangibles, and Fixtures and all other assets of Borrower and Tripos Realty located in the United States, whether now owned or hereafter acquired, and all proceeds thereof, subject only to Permitted Security Interests.

Collateral Assignments; Grant of Security Interest.

Collateral assignments of promissory notes executed by any Covered Person and payable to the order of Borrower and a grant of Security Interest in Borrower's trademarks patents and copyrights, all pursuant to documents satisfactory to Lender, each subject to no other Security Interests except Permitted Security Interests.

Pledge Agreements.

Membership pledge agreement executed by Borrower pledging 100% of the membership interests in Tripos Realty, 65% of its stock interests in Tripos UK Holdings Limited, and a stock pledge agreement executed by Tripos UK Holdings Limited pledging 65% of its stock in Tripos UK Limited and Tripos Receptor Research Limited. On or before the UK Effective Date, Pledge agreement executed by Borrower pledging the Brokerage Account to Lender.

Guaranty.

The unconditional guaranty of the Loan Obligations by Tripos Realty (other than with respect to the Term Loan, on which Tripos Realty is a direct obligor) (the "Guarantor"), pursuant to a guaranty in the form of Exhibit 8.5 attached hereto (the "Guaranty").

Power of Attorney.

Borrower hereby authorizes Lender and irrevocably appoints Lender (acting by any of its officers) as agent and attorney-in-fact for Borrower and Guarantor (which appointment is coupled with an interest and is therefore irrevocable) to do any of the following until all of the Loan Obligations are fully and irrevocably paid and satisfied in full in cash, and the Commitments are terminated: (a) while there is an Existing Default (i) demand payment of any Account, (ii) enforce payment of any Account by legal proceedings or otherwise, and endorse Borrower's (or Guarantor's) name upon any items of payment and apply the proceeds thereof to the Loan Obligations as provided herein, (iii) exercise all or any of Borrower's (or Guarantor's) rights and remedies in proceedings brought to collect any Account, (iv) sell or assign any Account upon such terms, for such amount and at such time or times as Lender deems advisable; (v) settle, adjust, compromise, extend, or renew any account, (vi)  discharge and release any Account, (vii) prepare, file and sign Borrower's (or Guarantor's) name on any proof of claim in bankruptcy or other similar documents against an Account Debtor; (viii) notify the postal authorities of any change of the address for delivery of Borrower's (or Guarantor's) mail to any address designated by Lender, and open and process all mail addressed to any Covered Person (provided Lender uses reasonable efforts to deliver copies of all such mail to the Covered Person to which such mail was addressed (but Lender shall have no liability for failure to deliver such copies); (ix) endorse Borrower's (or Guarantor's) name on any verification of accounts and notices thereof to Account Debtors, and endorse Borrower's (or Guarantor's) name upon any chattel paper, document, instrument, invoice, or similar document or agreement relating to expenses of any of the foregoing, and (x) do anything that Lender deems necessary in its reasonable discretion to assure that the Loan Obligations are fully paid in cash; and (b) at any time until all of the Loan Obligations are fully and irrevocably paid and satisfied in full in cash, and the Commitments are terminated, execute in Borrower's (or Guarantor's) name and on Borrower's (or Guarantor's) behalf any financing statement or amendment thereto deemed necessary or appropriate by Lender to assure the perfection or continued perfection of Lender's Security Interests in the Collateral. The foregoing power of attorney and authorization shall be deemed automatically revoked upon the irrevocable payment in full in cash of all of the Loan Obligations, and the termination of the Commitments.

Conditions of Lending.

Conditions to Effectiveness of Amended and Restated Loan Agreement and Construction Letter of Credit.

Lender will have no obligation to fund the increase in the Term Loan, the initial Revolving Loan Advance or any subsequent Revolving Loan Advance or issue the Construction Letter of Credit unless:

Listed Documents and Other Items.

Financial Condition.

Default.

Perfection of Security Interests.

Representations and Warranties.

Material Adverse Change.

Pending Material Proceedings.

Payment of Fees.

Other Items.

Conditions to Subsequent Advances.

Lender will have no obligation to fund any Advance after the Amended and Restated Effective Date unless:

General Conditions.

Representations and Warranties.

Default.

No Material Adverse Change.

Additional Conditions to Issuance of Letters of Credit.

Neither the Construction Letter of Credit nor any other Letter of Credit will be issued unless at the time of such issuance:

Master Letter of Credit Agreement; Reimbursement Agreement.

With respect to any Letter of Credit to be issued pursuant to the Letter of Credit Commitment, Borrower has either executed and delivered to Lender a master letter of credit agreement satisfactory to Lender setting forth in more particularity the terms and conditions for the issuance of Letters of Credit, or Borrower has executed and delivered to Lender a reimbursement agreement satisfactory to Lender under which Borrower undertakes to reimburse to Lender on demand the amount of each draw on the Letter of Credit, as applicable, together with interest from the date of the draw at the rate set forth in Section 4.1. The conditions set forth in this Section 11.1 are not applicable to the Construction Letter of Credit.

No Prohibitions.

No order, judgment or decree of any Governmental Authority exists which purports by its terms to enjoin or restrain Lender from issuing the Construction Letter of Credit or a Letter of Credit, and no Law or request or directive (whether or not having the force of law) from any Governmental Authority with jurisdiction over Lender shall exist which prohibits, or requests that Lender refrain from, the issuance of letters of credit generally or the Construction Letter of Credit or a Letter of Credit in particular, or imposes upon Lender with respect to the Construction Letter of Credit or a Letter of Credit any restriction or reserve or capital requirement (for which Lender is not otherwise compensable by Borrower hereunder).

Conditions to Advances.

All of the conditions in Section 10.1 have been and remain satisfied.

Representations and Warranties.

The Representations and Warranties are true and correct as of the time of the issuance of such Letter of Credit.

No Default.

There is no Existing Default and no Default or Event of Default will occur as a result of the issuance of the Letter of Credit or the incurrence of Borrower's reimbursement obligations with respect thereto.

No Material Adverse Change.

Since the date of the most recent prior Advance or issuance of a Letter of Credit nothing has occurred which has had or is reasonably likely to have a Material Adverse Effect.

Construction Letter of Credit.

Lender will have no obligation to issue the Construction Letter of Credit unless:

Listed Documents and Other Items.

UK Loan Documents.

Reimbursement Agreements.

Representations and Warranties.

Except as otherwise described in the Disclosure Schedule attached hereto as Exhibit 12 (which references the specific Sections of this Section 12 hereof), Borrower represents and warrants to Lender as follows:

Organization and Existence.

Each Covered Person is duly organized and existing in good standing under the Laws of the state or nation of its organization, is duly qualified to do business and is in good standing in every state where the nature or extent of its business or properties require it to be qualified to do business, except where the failure to so qualify will not have a Material Adverse Effect. Each Covered Person has the power and authority to own its properties and carry on its business as now being conducted.

Authorization.

Each Covered Person is duly authorized to execute and perform every Loan Document to which such Covered Person is a party, and Borrower is duly authorized to borrow hereunder, and this Agreement and the other Loan Documents have been duly authorized by all requisite corporate action of each Covered Person. No consent, approval or authorization of, or declaration or filing with, any Governmental Authority (other than the filings for the purpose of perfection of the Security Interests in the Collateral), and no consent of any other Person, is required in connection with each Covered Person's execution, delivery or performance of this Agreement and the other Loan Documents, except for those already duly obtained (and except to the extent that the grant of a Security Interest in a Material Agreement requires the consent of any other Person).

Due Execution.

Every Loan Document to which a Covered Person is a party has been executed on behalf of such Covered Person by a Person duly authorized to do so.

Enforceability of Obligations.

Each of the Loan Documents to which a Covered Person is a party constitutes the legal, valid and binding obligation of such Covered Person, enforceable against such Covered Person in accordance with its terms, except to the extent that the enforceability thereof against such Covered Person may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally or by equitable principles of general application (and except to the extent that under applicable law the terms of a Material Agreement may limit the enforceability of a security interest therein or an assignment thereof).

Burdensome Obligations.

No Covered Person is a party to or bound by any Contract or is subject to any provision in the Charter Documents of such Covered Person which requires the Covered Person to take some action which would, if performed by such Covered Person, result in a Default or Event of Default either immediately or upon the elapsing of time.

Legal Restraints.

The execution and performance of any Loan Document by a Covered Person will not violate or constitute a default under the Charter Documents of such Covered Person, any Material Agreement of such Covered Person (except to the extent that the grant of a Security Interest in such Material Agreement to Lender would cause a breach by such Covered Person under such Material Agreement), or any Material Law, and will not, except as expressly contemplated or permitted in this Agreement, result in any Security Interest being imposed on any of such Covered Person's property.

Labor Disputes.

There is no pending or, to Borrower's knowledge, threatened, strike, work stoppage, unfair labor practice claim or other labor dispute against or affecting any Covered Person or its employees, which could reasonably be likely to have a Material Adverse Effect.

No Material Proceedings.

There are no Material Proceedings pending or, to the best knowledge of Borrower, threatened.

Material Licenses.

All Material Licenses have been obtained for each Covered Person.

Compliance with Material Laws.

Each Covered Person is in compliance with all Material Laws. Without limiting the generality of the foregoing:

Proceedings.

Hazardous Materials on Real Property.

Other Names.

Neither Borrower nor Tripos Realty has used any name other than the full name which identifies it in this Agreement, except that Borrower has previously used, but does not currently and will not in the future use, the name Tripos Associates, Inc., and Borrower is qualified to do business in California in the name California Tripos, Inc. The only trade name or trade style under which a Covered Person sells Inventory or creates Accounts or to which instruments in payment of Accounts are made payable, is the name which identifies such Covered Person in this Agreement.

Financial Statements.

The Financial Statements are and shall remain complete and correct in all material respects, have been prepared in accordance with GAAP, and fairly reflect the financial condition, results of operations and cash flows of the Persons covered thereby as of the dates and for the periods stated therein, subject, in the case of monthly and quarterly Financial Statements, to normal year-end adjustments made in accordance with GAAP.

No Change in Condition.

There has been no change which has or is reasonably likely to have a Material Adverse Effect on any Covered Person.

No Defaults.

No Covered Person has breached or violated or has defaulted under any Material Agreement, or has defaulted with respect to any Material Obligation of such Covered Person. No Default has occurred which is continuing and no Event of Default has occurred.

Solvency.

Borrower is solvent prior to and after giving effect to the making of the Term Loan and the initial Revolving Loan Advance on the Amended and Restated Effective Date.

Encumbrances.

None of the real property purported to be owned by a Covered Person and located in the United States is subject to any Encumbrances other than Encumbrances existing on October 1, 2002 and previously disclosed to Lender or Encumbrances in favor of Lender.

Real Property.

Section 12.17 of the Disclosure Schedule contains a correct and complete list of (i) the street addresses and a general description of all real property owned by each Covered Person, and (ii) a list of all leases and subleases of real property by each Covered Person, with such Covered Person identified for each as the lessee, sublessee, lessor, or sublessor, as is the case, together with the street addresses and a general description of the real property involved and the names of the other parties to such leases and subleases. Each of such leases and subleases is valid and enforceable in accordance with its terms and is in full force and effect, and no material default by any party to any such lease or sublease exists.

Indebtedness.

No Covered Person has any Indebtedness except Permitted Indebtedness (as specified in Section 15.3 hereof).

Investments.

No Covered Person has any Investments in other Persons except Permitted Investments.

Indirect Obligations.

No Covered Person has any Indirect Obligations except Permitted Indirect Obligations.

Capital Leases.

No Covered Person has an interest as a lessee under any Capital Leases other than Capital Leases that do not cause a breach on any limitation herein on Capital Expenditures.

Tax Liabilities; Governmental Charges.

Each Covered Person has filed or caused to be filed all tax reports and returns required to be filed by it with any Governmental Authority, except where extensions have been properly obtained. Each Covered Person has paid or made adequate provision for payment of all Taxes of such Covered Person, except Taxes which are being diligently contested in good faith by appropriate proceedings and as to which such Covered Person has established adequate reserves in conformity with GAAP. No Security Interest for any such Taxes has been filed and no claims are being asserted with respect to any such Taxes which, if adversely determined, has or is reasonably likely to have a Material Adverse Effect on such Covered Person. Borrower was audited in 1998 by the IRS with respect to its 1996 and 1997 federal income taxes, and no material adjustments in taxes were made as a result of such audit; the IRS has not notified any Covered Person that it intends to perform any other audit. There are no material unresolved issues o r other matters concerning any liability of a Covered Person for any Taxes which, if adversely determined, has or is reasonably likely to have a Material Adverse Effect on such Covered Person.

Pension Benefit Plans.

All Pension Benefit Plans maintained by each Covered Person or an ERISA Affiliate of any Covered Person qualify under Section 401 of the Code and are in compliance with the provisions of ERISA, except where the failure to comply could not reasonably be likely to have a Material Adverse Effect.

Welfare Benefit Plans.

No Covered Person or ERISA Affiliate of any Covered Person maintains a Welfare Benefit Plan that has a liability which, if enforced or collected, has or is reasonably likely to have a Material Adverse Effect. Each Covered Person and each ERISA Affiliate of any Covered Person has complied in all material respects with the applicable requirements of Section 4980B of the Code pertaining to continuation coverage as mandated by COBRA.

Retiree Benefits.

No Covered Person or ERISA Affiliate of any Covered Person has an obligation to provide any Person with any medical, life insurance, or similar benefit following such Person's retirement or termination of employment (or to such Person's beneficiary subsequent to such Person's death) other than (i) such benefits provided to Persons at such Person's sole expense and (ii) obligations under COBRA.

Distributions

No Distribution has been declared, paid or made upon or in respect of any capital stock or other securities of Borrower on and after the Amended and Restated Effective, except as expressly permitted hereby.

Chief Place of Business; Locations of Collateral.

As of the Amended and Restated Effective Date:

Chief Place of Business

Location of Books, Records and Chattel Paper

Location of Tangible Collateral

State of Collateral and Other Property

Each Covered Person has good and marketable or merchantable title to all real and personal property purported to be owned by it or reflected in the Financial Statements, except for personal property sold in the ordinary course of business after the date of the Financial Statements. There are no Security Interests on any of the property purported to be owned by any Covered Person, including the Collateral, except Permitted Security Interests. Each tangible item of Personal Property Collateral purported to be owned by a Covered Person is in good operating condition and repair and is suitable for the use to which it is customarily put by its owner. Without limiting the generality of the foregoing:

Accounts

Inventory

Equipment

Intellectual Property

Documents, Instruments and Chattel Paper

Negative Pledges

Neither Borrower nor Guarantor is a party to or bound by any Material Contract, other than the Loan Documents, which prohibits the creation or existence of any Security Interest upon or assignment or conveyance of any of the Collateral.

Margin Stock

No Covered Person is engaged and no Covered Person will engage, principally or as one of its important activities, in the business of extending credit for the purpose of purchasing or carrying margin stock (within the meaning of Regulation U), and no part of the proceeds of any Advance will be used to purchase or carry any such margin stock or to extend credit to others for the purpose of purchasing or carrying any such margin stock or for any purpose which violates, or which would be inconsistent with, the provisions of Regulation U or Regulation G.

Securities Matters

No proceeds of any Advance will be used to acquire any security in any transaction which is subject to Sections 13 and 14 of the Securities Exchange Act of 1934.

Investment Company Act

No Covered Person is an investment company registered or required to be registered under the Investment Company Act of 1940, or a company controlled (within the meaning of such Investment Company Act) by such an investment company or an affiliated person of, or promoter or principal underwriter for, an investment company, as such terms are defined in the Investment Company Act of 1940. No Covered Person is subject to regulation under the Public Utility Holding Company Act of 1935, the Federal Power Act, the Interstate Commerce Act or any other Law limiting or regulating its ability to incur Indebtedness for money borrowed.

No Material Misstatements or Omissions

Neither the Loan Documents, any of the Financial Statements nor any statement, list, certificate or other information furnished or to be furnished by any Covered Person to Lender in connection with the Loan Documents or any of the transactions contemplated thereby contains any untrue statement of a material fact, or omits to state a material fact necessary to make the statements therein not misleading. Each Covered Person has disclosed to Lender everything known to a Responsible Officer regarding the business, operations, property, financial condition, or business prospects of itself and every Covered Person that has or is reasonably likely to have a Material Adverse Effect on any Covered Person.

No Loans to Insiders

None of the proceeds of the Loan will be used directly or indirectly to fund a personal loan to or for the benefit of a director or executive officer of Borrower or any Covered Person.

Survival

All representations and warranties, covenants and agreements, contained herein, in any other Loan Document, or in any certificate delivered by any Covered Person pursuant hereto or thereto, as the same may be updated, modified or amended from time to time upon a Covered Person's written request to Lender of such update, modification or amendment and upon Lender's written approval of the same shall survive execution of each of the Loan Documents and the making of every Advance, and may be relied upon by Lender as being true and correct as of the date when made or deemed made or reaffirmed until all of the Loan Obligations are fully and indefeasibly paid in full in cash.

Affirmative Covenants

Borrower covenants and agrees that, while any of the Commitments remains in effect, or while the Construction Letter of Credit or any Letters of Credit are outstanding, and until all of the Loan Obligations are fully and indefeasibly paid in full in cash, Borrower shall do, and cause each Covered Person to do, each of the following:

Use of Proceeds

Subject to the terms and conditions hereof, the proceeds of (a) the Revolving Loan Advances shall be used for Capital Expenditures, as well as for general corporate and working capital purposes, (b) the Term Loan shall be used to refinance the existing indebtedness of Tripos Realty secured by the Mortgaged Property and for Capital Expenditures, as well as for general corporate and working capital purposes.

Corporate Existence

Each Covered Person shall maintain its existence in good standing and shall maintain in good standing its right to transact business in those states or countries in which it is now or hereafter doing business, except where the failure to so qualify will not have and will not be reasonably likely to have a Material Adverse Effect. Each Covered Person shall obtain and maintain all Material Licenses for such Covered Person.

Maintenance of Property and Leases

Each Covered Person shall maintain in good condition and working order, and repair (ordinary wear and tear excepted) and replace as required, all buildings, equipment, machinery, fixtures and other real and personal property whose useful economic life to such Covered Person has not elapsed and which is reasonably necessary for the ordinary conduct of the business of such Covered Person. Each Covered Person shall maintain in good standing and free of material defaults all of its leases of buildings, equipment, machinery, fixtures and other real and personal property whose useful economic life to such Covered Person has not elapsed and which is necessary for the ordinary conduct of the business of such Covered Person.

Inventory

Each Covered Person shall keep its Inventory in good and merchantable condition at its own expense and shall hold such Inventory for sale or lease, or to be furnished in connection with the rendition of services, in the ordinary course of such Covered Person's business, on terms which are customary for the industry in which such Covered Person operates. All such Inventory shall be produced in accordance with the Federal Fair Labor Standards Act of 1938 and all rules, regulations, and orders thereunder.

Insurance

Each Covered Person shall at all times keep insured or cause to be kept insured, in insurance companies having a rating of at least "A" by Best's Rating Service, all property owned by it of a character usually insured by others carrying on businesses similar to that of such Covered Person in such manner and to such extent and covering such risks as such properties are usually insured. Each Covered Person shall carry business interruption insurance at such levels as are acceptable to Lender. Each Covered Person shall at all times carry insurance, in insurance companies having a rating of at least "A" by Best's Rating Service, against liability on account of damage to persons or property (including product liability insurance and insurance required under all Laws pertaining to workers' compensation) and covering all other liabilities common to such Covered Person's business, in such manner and to such extent as such coverage is usually carried by others conducting businesses similar to that of such Covered Person. All policies of liability insurance maintained hereunder shall name Lender as an additional insured; all fire and casualty policies of insurance maintained by Borrower hereunder shall reflect Lender's interest therein as mortgagee under a standard New York or Union mortgagee clause. If an Event of Default has occurred, Lender is authorized, but not obligated, as the attorney-in-fact for Borrower, (i) to adjust and compromise proceeds payable under such policies of insurance, (ii) to collect, receive and give receipts for such proceeds in the name of Borrower and Lender, and (iii) to endorse Borrower's name upon any instrument in payment thereof. Such power granted to Lender shall be deemed coupled with an interest and shall be irrevocable. All policies of insurance maintained hereunder shall contain a clause providing that such policies may not be canceled, reduced in coverage or otherwise modified without 30 days prior written notice to Lender. Borrower shall upon request of Lender at any time furni sh to Lender updated evidence of insurance (in the form required as a condition to Lender's lending hereunder) for such insurance.

Payment of Taxes and Other Obligations

Each Covered Person shall promptly pay and discharge or cause to be paid and discharged, as and when due, any and all income taxes, federal or otherwise, lawfully assessed and imposed upon any of the Collateral or its other property, and any and all lawful taxes, rates, levies, and assessments whatsoever upon its properties and every part thereof, or upon the income or profits therefrom and all claims of materialmen, mechanics, carriers, warehousemen, landlords and other like Persons for labor, materials, supplies, storage or other items or services which if unpaid might be or become a Security Interest or charge upon any of the Collateral or its other property; provided, however, that a Covered Person may diligently contest in good faith by appropriate proceedings the validity of any such taxes, rates, levies, or assessments, provided such Covered Person has established adequate reserves therefor in conformity with GAAP on the books of such Covered Person, and no Security Interest, other th an a Permitted Security Interest, results from such non-payment.

Compliance With Laws

Each Covered Person shall comply with all Material Laws.

Discovery and Clean-Up of Hazardous Material

Upon any Responsible Officer of any Covered Person receiving notice or becoming aware of any violation of Environmental Laws or any similar notice described in Section 14.10.2, or upon any Covered Person otherwise discovering Hazardous Material on any property owned or leased by such Borrower which is in violation of, or which would result in liability under, any Environmental Law, Borrower shall: (i) promptly take such acts as may be necessary to prevent danger or harm to the property or any person therein as a result of such Hazardous Material; and (ii) take all necessary steps to initiate and expeditiously complete all removal, remedial, response, corrective and other action to eliminate any such environmental problems, and keep Lender informed of such actions and the results thereof.

Termination of Pension Benefit Plan

No Covered Person or ERISA Affiliate of any Covered Person shall terminate or amend any Pension Benefit Plan maintained by such Covered Person or such ERISA Affiliate if such termination or amendment would result in any liability to such Covered Person or such ERISA Affiliate under ERISA, which could reasonably be likely to have a Material Adverse Effect, or any increase in current liability for the plan year for which such Covered Person or such ERISA Affiliate is required to provide security to such Pension Benefit Plan under the Code, which could reasonably be likely to have a Material Adverse Effect.

Notice to Lender of Material Events

Borrower shall, promptly upon any Responsible Officer of Borrower or Tripos Receptor Research Limited obtaining knowledge or notice thereof, give notice to Lender of (i) any breach of any of the covenants in Section 14, 15, or 16; (ii) any Default or Event of Default; (iii) the commencement of any Material Proceeding; and (iv) any loss of or damage to any assets of a Covered Person or the commencement of any proceeding for the condemnation or other taking of any of the assets of a Covered Person, or if such loss, damage or proceeding has or is reasonably likely to have a Material Adverse Effect on such Covered Person. In addition,

Material Proceeding

Violation of Material law

Default

Indebtedness of a Covered Person

Material Labor Dispute

Name Change

Material Adverse Effect

Borrowing Officer

Borrower shall keep on file with Lender at all times an appropriate instrument naming each Borrowing Officer.

Maintenance of Security Interests of Security Documents

Preservation and Perfection of Security Interests

Collateral Held by Warehouseman, Bailee, etc.

Compliance With Terms of Security Documents

Accounting System; Tracing of Proceeds.

Each Covered Person shall maintain a system of accounting established and administered in accordance with GAAP. Each Covered Person shall maintain materially accurate and reasonably detailed records of proceeds of the Loans and substantial transfers of proceeds of the Loans (i) received by it from the Lender, (ii) transferred from it to any other Covered Person, and (iii) received by it from another Covered Person. Borrower acknowledges that (i) its ability to obtain the Loans hereunder is made possible by the fact that Tripos Realty is guarantying the Loan Obligations and Tripos UK Holdings is providing certain Collateral to secure the Loan Obligations, (ii) the business operations of each Covered Person complement one another, and such entities have a common business purpose, and (iii) the proceeds of Advances hereunder will benefit each Covered Person, severally and jointly, regardless of which Covered Person receives part or all of any Advance.

Financial Statements

Borrower shall deliver to Lender:

Annual Financial Statements

Quarterly Financial Statements

Monthly Financial Statements.

Other Financial Information

Borrower shall also deliver the following to Lender, as specified below:

Other Reports or Information Concerning Accounts, or Inventory

Stockholder and SEC Reports

Pension Benefit Plan Reports

Tax Returns

Review of Accounts

Not less often than annually, and promptly at Lender's request if there is an Existing Default, Borrower shall conduct a review of its Accounts, bad debt reserves, and collection histories of Account Debtors and promptly following such review provide Lender with a report of such review in form and detail satisfactory to Lender.

Inventory

Not less often than annually, and promptly at Lender's request if there is an Existing Default, Borrower shall conduct a physical count of its Inventory and promptly following the completion of such count provide Lender with a report thereof in form and detail satisfactory to Lender, including the value of such Inventory.

Annual Projections

Prior to the first day of each fiscal year of Borrower, projected balance sheets, statements of income and expense, and statements of cash flows for Borrower as of the end of, and for each quarter of, such fiscal year.

Other Information

Upon the request of Lender, Borrower shall promptly deliver to Lender such other information about the business, operations, revenues, financial condition, property, or business prospects of any Covered Person as Lender may, from time to time, reasonably request.

Exams by Lender

Lender or Persons authorized by and acting on behalf of Lender may at any time during normal business hours examine the books and records and inspect any of the property of each Covered Person from time to time upon reasonable notice (except that during an Existing Default, no prior notice shall be required) to such Covered Person, and in the course thereof may make copies or abstracts of such books and records and discuss the affairs, finances and books and records of such Covered Person with its accountants, officers and employees. Each Covered Person shall cooperate with Lender and such Persons in the conduct of such exams and shall deliver to Lender any instrument necessary for Lender to obtain records from any service bureau maintaining records for such Covered Person. Borrower shall reimburse Lender for all reasonable costs and expenses actually incurred by it in conducting each exam.

Verification of Accounts, and Notices to Account Debtors

Lender shall have the right at any time to verify the validity and amount of any Account, and any other matter relating to an Account by communicating in writing or orally directly with the Account Debtor or any Person who represents or Lender believes represents the Account Debtor.

Access to Officers and Auditors

Each Covered Person shall permit Lender and Persons authorized by Lender to discuss the business, operations, revenues, financial condition, property, or business prospects of such Covered Person with its officers, employees, accountants and independent auditors as often as Lender may reasonably request in its discretion and Lender shall have a bona fide reason for such request, and such Covered Person shall direct such officers, employees, accountants and independent auditors to cooperate with Lender and make full disclosure to Lender of those matters that they may deem relevant to the continuing ability of Borrower timely to pay and perform the Loan Obligations except as provided in this Agreement. Lender agrees that it will not disclose to third Persons any information that it obtains about any Covered Person or its operations or finances. Lender may, however, disclose such information to all of its officers, attorneys, auditors, accountants, bank examiners, agents and representatives who have a need t o know such information in connection with the administration, interpretation or enforcement of the Loan Documents or the lending and collection activity contemplated therein or to the extent required by Law or a Governmental Authority. Lender shall advise such Persons that such information is to be treated as confidential and Lender is contractually obligated to keep such information confidential. Lender may also disclose such information in any documents that it files in any legal proceeding to pursue, enforce or preserve its rights under the Loan Documents to the extent that Lender's counsel advises it that such disclosure is reasonably necessary. Lender's non-disclosure obligation shall not apply to any information that (i) is disclosed to Lender by a third Person not affiliated with or employed by Borrower who does not have a duty of non-disclosure, or (ii) becomes publicly known other than as a result of disclosure by Lender.

Intercompany Indebtedness

Any Indebtedness owing from Borrower to any other Covered Person from time to time, shall, at all times during which the Commitments shall be outstanding or any Loan Obligations shall be owing to Lender, be unsecured and subordinated to the indefeasible prior repayment in full in cash of all of the Loan Obligations.

Pfizer

Notify Lender in the event (a) the Pfizer Contract is modified to reduce the total contract deliverables due thereunder by ten percent (10%) or more, or (b) completion of the Pfizer Contract is extended for more than one quarter.

Further Assurances

Borrower and each other Covered Person shall execute and deliver, or cause to be executed and delivered, to Lender such documents and agreements, and shall take or cause to be taken such actions, as Lender may from time to time reasonably request to carry out the terms and conditions of this Agreement and the other Loan Documents. During the continuance of an Existing Default and at any time thereafter, Borrower covenants and agrees that the Lender may, in its sole and absolute discretion, proceed directly against Borrower, or any other Person liable for the payment or performance of the Loan Obligations, or any or all of Borrower's property, or any combination of the foregoing, in one or more claims, actions or proceedings, whether or not any such claims, actions or proceedings are instituted simultaneously or at different times.

Negative Covenants

Borrower covenants and agrees that, while any of the Commitments remain in effect and until all Letters of Credit, including without limitation the Construction Letter of Credit, have expired and all of the Loan Obligations are fully and indefeasibly paid in full in cash, Borrower shall not, directly or indirectly, do any of the following, or permit any other Covered Person to do any of the following, without the prior written consent of Lender:

Sale of Interests

Sell or otherwise dispose of Borrower's interest in any Subsidiary or Affiliate, provided, however, that Borrower may sell or otherwise dispose of its interests in Arena Pharmaceuticals, Inc. for consideration deemed fair and reasonable by the board of directors of Borrower.

Investments

Make any Investments in any other Person except the following:

United States or Qualified Financial Institution

Existing on Amended and Restated Effective Date

Notes Collaterally Assigned to Lender

Customary Trade Terms

General Investments

Indebtedness.

Create, incur, assume, or allow to exist any Indebtedness as to any Covered Person of any kind or description, except the following:

Incurred in Ordinary Course of Business

The Loan Obligations and the UK Loan Obligations

Security Interests

Capital Leases

Operating Leases

Pursuant to Open Account

Existing and Disclosed

General Indebtedness.

Security Interests.

Create, incur, assume or allow to exist any Security Interest upon all or any part of its property, real or personal, now owned or hereafter acquired, except the following:

In Accordance With GAAP

Arising Out Of Legislation

Security Deposits

Security Interests Imposed By Law

Securing Payment

Securing Operating Leases

Securing Indebtedness

Disclosed in Section 12.28

Security Interests in Property of Foreign Subsidiaries

Security Interests to Secure Capital Leases

RESERVED.

Capital Leases.

Enter into any Capital Lease after the Amended and Restated Effective Date with an outstanding balance from time to time, which when aggregated with the original outstanding balance(s) of all other Capital Leases entered into after the Amended and Restated Effective Date, exceeds $4,200,000.

Change of Control.

Merge or consolidate with or into another Person, or permit any Person, other than the current shareholders, to become the record or beneficial owner, directly or indirectly, of securities representing 30% or more of the voting power of any Covered Person's then outstanding securities, or acquiring a sufficient interest to elect a majority of the board of directors, elect or appoint the managing partner(s) or otherwise direct the day-to-day control of any Covered Person, or in the case of any Covered Person other than Borrower, permit any Person, other than another Covered Person, to obtain any direct or indirect ownership interest in such Covered Person; except that Borrower may reincorporate as a Delaware corporation to change its state of incorporation provided Borrower has delivered at least 30 days' prior notice to Lender of the proposed change, the successor entity succeeds to all of Borrower's assets, rights, obligations and liabilities (including the Loan Obligations) upon such restructuring, and Borrower executes such additional documents in connection therewith as Lender may reasonably require.

Distributions.

Declare or pay any Distribution.

Indirect Obligations.

Create, incur, assume or allow to exist any Indirect Obligations, except for Indirect Obligations which are Loan Obligations or UK Loan Obligations (or with respect to such obligations), and except for Indirect Obligations of Borrower existing or contemplated on the Amended and Restated Effective Date and disclosed to Lender on Exhibit 12.

Capital Structure; Equity Securities.

Make any change in the capital structure of any Covered Person which has or is reasonably likely to have a Material Adverse Effect; or issue or create any securities (except for director qualifying shares in the case of Covered Persons not organized under the laws of the United States) of any Covered Person other than Borrower, except as approved in advance by Lender (such approval not to be unreasonably withheld).

Change of Business.

Engage in any business other than the business currently conducted by Borrower or a business reasonably related thereto.

Transactions With Affiliates; Loans to Insiders.

Enter into or be a party to any transaction or arrangement, including the purchase, sale or exchange of property of any kind or the rendering of any service with any Affiliate, or make any loans or advances to any Affiliate, in each case on terms more favorable than could be obtained with independent third parties. Directly or indirectly: (a) after the Amended and Restated Effective Date, fund a personal loan to or for the benefit of a director or executive officer of Borrower or any Covered Person, other than travel expense advances and company credit card advances in the ordinary course of business, or (b) take any action in violation of, or otherwise prohibited by, the Sarbanes-Oxley Act of 2002.

Cash Transfers.

Cause or permit any cash (whether proceeds of the Loans or otherwise) to be transferred from Borrower to any Covered Person at any time except as permitted or contemplated by Section 15.2.3 or Section 15.12.

No Default on Indebtedness or Material Agreements.

Default upon or fail to pay any Indebtedness for borrowed money in excess of $100,000.00, as the same matures, or breach, violate, or be in default under or any Material Agreement and fail to cure such failure to pay, breach, violation, or default within the applicable cure period provided therein.

Conflicting Agreements.

Enter into any agreement that would require a Covered Person to take action which would result in a Default or Event of Default either immediately or upon the elapsing of time.

Fiscal Year.

Change its fiscal year end, which is currently December 31.

New Subsidiaries.

Organize, create or acquire any Subsidiary other than those in existence on the date hereof and disclosed on the Disclosure Schedule, unless simultaneously with such Person becoming a Subsidiary, such Person becomes a Borrower or a Guarantor under this Agreement and executes any joinder agreements or other documents deemed necessary by Lender to evidence such Subsidiary's joint and several liability for the Loan Obligations.

Transactions Having a Material Adverse Effect or Causing a Default.

Enter into any transaction which has or is reasonably likely to have a Material Adverse Effect; or enter into any transaction, or take or contemplate taking any other action, or omit or contemplate omitting to take any action, which any Responsible Officer knows, or reasonably should know, is likely to cause a Default or Event of Default hereunder.

Disposal of Property.

Sell, transfer, exchange, lease, license, or otherwise dispose of any of its assets to any Person, including, without limitation, to any other Covered Person except in the ordinary course of business. Any Covered Person may sell, transfer or otherwise dispose of obsolete or unusable equipment or other equipment, other than in the ordinary course of business, having an orderly liquidation value no greater than $100,000 in the aggregate for all Covered Persons in any fiscal year of Borrower unless Lender otherwise consents in writing (such consent not to be unreasonably withheld).

Intellectual Property.

Cause or permit ownership of any Intellectual Property to be transferred from Borrower to any other Covered Person.

Acquisitions.

Except for Permitted Investments, acquire stock or any other equity interest in a Person sufficient for such Person to become a Subsidiary or Affiliate of a Covered Person, or acquire all or substantially all of the assets of a Person (including all or substantially all of the operating assets of an operating division of a Person), or make any acquisition of property not in the ordinary course of business consistent with past practices.

Financial Covenants.

Special Definitions.

As used in this Section 16 and elsewhere herein, the following capitalized terms have the following meanings:

All other capitalized terms used in this Section 16 shall have the meanings given them, and shall be determined, under GAAP. All calculations shall be for Borrower and its Subsidiaries on a consolidated basis.

Maximum Total Funded Indebtedness to Shareholder's Equity.

Borrower covenants and agrees that the ratio of Borrower's Total Funded Indebtedness to the sum of Borrower's Total Funded Indebtedness, plus Shareholder's Equity, calculated as of the last day of each fiscal quarter, beginning December 31, 2002, shall at no time be greater than (a) 1.0:4.0 for the quarter ending December 31, 2002 through and including the quarter ending December 31, 2004, (b) 1.0:5.0 for the quarter ending March 31, 2005 and for each quarter thereafter.

RESERVED.

Minimum Fixed Charge Coverage Ratio.

Borrower covenants and agrees that the ratio of Borrower's EBITDA plus gains on the sale of shares of Arena Pharmaceuticals, Inc. to Borrower's Fixed Charges (a) for the preceding three (3) month period, calculated for December 31, 2002 shall at no time be less than 1.20 to 1.00, (b) for the preceding six (6) month period, calculated for March 31, 2003 shall at no time be less than 1.20 to 1.00, (c) for the preceding nine (9) month period, calculated for June 30, 2003 shall at no time be less than 1.20 to 1.00, and (d) for the preceding twelve (12) month period, calculated for September 30, 2003 and for the last day of each fiscal quarter thereafter, shall at no time be less than 1.20 to 1.00.

Minimum EBITDA.

Borrower covenants and agrees that Borrower's EBITDA, calculated as of the last day of each fiscal quarter (a) for the preceding twelve (12) month period, calculated for December 31, 2003 shall at no time be less than $2,950,000, (b) for the preceding twelve (12) month period, calculated for March 31, 2004, shall at no time be less than $3,500,000, (c) for the preceding twelve (12) month period, calculated for June 30, 2004, shall at no time be less than $6,400,000, (d) for the preceding twelve (12) month period, calculated for September 30, 2004, shall at no time be less than $7,850,000, and (e) for the preceding twelve (12) month period, calculated for December 31, 2004 and for the last day of each fiscal quarter thereafter, shall at no time be less than $9,000,000.

Maximum Non-TRR Capital Expenditures.

Borrower's Non-TRR Capital Expenditures for the preceding twelve (12) month period, calculated as of the last day of each fiscal quarter, beginning September 30, 2003, shall not exceed $2,000,000.

Minimum Shareholders Equity.

Borrower covenants and agrees that Borrower's Shareholders Equity, calculated as of the last day of each fiscal quarter commencing with the fiscal quarter ending December 31, 2002, shall not be less than (a) 90% of Borrower's Shareholders Equity as of September 30, 2002, plus (b) for the fiscal quarter ending December 31, 2002 and for each fiscal quarter thereafter, an amount equal to the sum of the minimum amount required to be maintained for the immediately preceding fiscal quarter plus 90% of the Borrower's Net Income (but not less than zero) for such current fiscal quarter, plus (c) for the fiscal quarter ending December 31, 2002 and for each fiscal quarter thereafter, an amount equal to 100% of the amounts received for the issuance of stock of Borrower, if any. The described calculation of Borrower's Shareholders Equity may be performed, in Lender's sole discretion, exclusive of (i) all gains and losses caused by foreign currency translation adjustments, (ii) preferred stock of Borrowe r, and (iii) the book value of Borrower's equity holdings.

Default.

Events of Default.

Any one or more of the following shall constitute an event of default (an "Event of Default") under this Agreement:

Failure to Pay Principal or Interest.

Failure to Pay Other Amounts Owed to Lender.

Failure to Pay Amounts Owed to Other Persons.

Representations or Warranties.

Certain Covenants.

Other Covenants.

Acceleration of Other Indebtedness.

Default Under Other Agreements.

Bankruptcy; Insolvency; Etc.

Judgments; Attachment; Settlement; Etc.

Pension Benefit Plan Termination, Etc.

Liquidation or Dissolution.

Seizure of Assets.

Loan Documents; Security Interests.

Loss to Collateral.

Cross-Default.

Material Adverse Change.

Guaranty Default.

Construction Letter of Credit.

Rights and Remedies in the Event of Default.

Termination of Commitments.

Acceleration.

Right of Set-off.

Notice to Account Debtors.

Entry Upon Premises and Access to Information.

Borrower's Obligations.

Secured Party Rights.

Miscellaneous.

Application of Funds.

Limitation of Liability; Waiver.

Lender shall not be liable to Borrower or any other Covered Person as a result of any commercially reasonable possession, repossession, collection or sale by Lender of Collateral; and to the extent permitted by applicable law Borrower hereby waives all rights of redemption from any such sale and the benefit of all valuation, appraisal and exemption Laws. If Lender seeks to take possession of any of the Collateral by replevin or other court process after an Event of Default, Borrower hereby irrevocably waives (i) the posting of any bonds, surety and security relating thereto required by any statute, court rule or otherwise as an incident to such possession, (ii) any demand for possession of the Collateral prior to the commencement of any suit or action to recover possession thereof, (iii) any requirement that Lender retain possession and not dispose of any Collateral until after trial or final judgment, and (iv) to the extent permitted by applicable Law, all rights to notice and hearing prior to the exerci se by Lender of its right to repossess the Collateral without judicial process or to replevy, attach or levy upon the Collateral without notice or hearing. No Lender shall have any obligation to preserve rights to the Collateral or to marshall any Collateral for the benefit of any Person.

Reasonable Notice.

Any notice of intended action required to be given by Lender (including notice of a public or private sale of Collateral), if given as provided in Section 22.1 at least 10 days prior to such proposed action, shall be effective and constitute reasonable and fair notice to Borrower.

Changes in Circumstances.

Compensation for Increased Costs and Reduced Returns; Capital Adequacy.

Increased Costs or Reduced Returns to Lender.

Capital Adequacy.

Notice to Borrower.

Limitations on Eurodollar Loans.

If on or prior to the first day of any Interest Period for any Eurodollar Loan:

Market Failure.

Inadequate Reflection of Cost.

then Lender will give Borrower prompt notice thereof, and while such condition remains in effect, Lender will have no obligation to make additional Advances that will be Eurodollar Loans, to continue Eurodollar Loans, or to convert Prime Rate Loans into Eurodollar Loans.

Illegality.

Notwithstanding any other provision of this Agreement, in the event that it becomes unlawful for Lender or the Lending Office to make Advances that will be Eurodollar Loans or maintain Eurodollar Loans hereunder, then Lender shall promptly notify Borrower thereof and Lender's obligation to do so or to convert Prime Rate Loans into Eurodollar Loans shall be suspended until such time as Lender may again do so, and Lender's outstanding Eurodollar Loans shall be converted into Prime Rate Loans in accordance with Section 18.5.

Compensation.

Upon the request of Lender, Borrower shall pay to Lender such amount or amounts as will be sufficient (in the reasonable determination of Lender) to compensate it for any loss, cost, or expense (including loss of anticipated profits) incurred by it as a result of:

Early Payment.

Failure to Take Advances.

If Lender claims compensation under this Section 18.4, Lender shall furnish a certificate to Borrower that states the amount to be paid to it hereunder and includes a description in reasonable detail of the method used by Lender in calculating such amount. Borrower shall have the burden of proving that the amount of any such compensation calculated by Lender is not correct. Any compensation payable by Borrower to Lender under this Section shall be payable without regard to whether Lender has funded any Advance or Eurodollar Loan through the purchase of deposits in an amount or of a maturity corresponding to the deposits used as a reference in determining the Eurodollar Rate as provided herein.

Treatment of Affected Revolving Loans.

If the obligation of Lender to make an Advance that will be a Eurodollar Loan or to continue any Eurodollar Loan or to convert any Prime Rate Loan into a Eurodollar Loan shall be suspended pursuant to Section 18.2 or 18.3 each such Revolving Loan shall be automatically and immediately converted into a Prime Rate Loan on the last day of its Interest Period (or, in the case of a conversion required by Section 18.3, on such earlier date as Lender may specify to Borrower). Unless and until Lender gives notice as provided below that the circumstances specified in Section 18.2 or 18.3 that gave rise to such conversion no longer exist:

Payments.

Prime Rate.

Lender shall give prompt notice to Borrower if and when the circumstances specified in Section 18.2 or 18.3 that gave rise to the conversion of Revolving Loans pursuant to this Section 18.5 no longer exist.

Taxes.

Gross-Up.

All payments by Borrower to or for the account of Lender hereunder or under any other Loan Document shall be made free and clear of and without deduction for all present or future Taxes, excluding franchise Taxes and Taxes imposed on Lender's net income, by the jurisdiction under the Laws of which Lender is organized or the Lending Office is located or any political subdivision thereof. If Borrower is required by Law to deduct any Taxes from or in respect of any sum payable under this Agreement or any other Loan Document to Lender, (i) the sum payable shall be increased as necessary so that after making all required deductions (including deductions applicable to additional sums payable under this Section) Lender receives an amount equal to the sum it would have received had no such deductions been made, (ii) Borrower shall make such deductions, (iii) Borrower shall pay the full amount deducted to the relevant taxation authority or other authority in accordance with applicable Law, and (iv) Borrower shall furnish to Lender, at its address referred to herein, the original or a certified copy of a receipt evidencing payment thereof. In addition, Borrower agrees to pay any and all present or future Impositions. Impositions include stamp or documentary taxes and any other excise or property taxes or charges or similar levies which arise from the Loan Obligations, any payment made under this Agreement or any other Loan Document or from the execution or delivery of, or otherwise with respect to, the Loan Obligations, this Agreement or any other Loan Document. Borrower agrees to indemnify Lender for the full amount of all Impositions and Taxes, excluding franchise Taxes and Taxes imposed on Lender's net income, (including any such Taxes or Impositions imposed or asserted by any jurisdiction on amounts payable under this Section) paid by Lender and any liability (including penalties, interest and expenses) arising therefrom or with respect thereto. Within thirty days after the date of any payment of Taxes, Borrower s hall furnish Lender the original or a certified copy of a receipt evidencing such payment.

Lender's Undertaking.

If Borrower is required to pay additional amounts to or for the account of Lender pursuant to Section 19.1, then Lender will use reasonable efforts to change the jurisdiction of the Lending Office so as to eliminate or reduce any such additional payment which may thereafter accrue if such change, in the judgment of Lender, is not otherwise disadvantageous to Lender.

Usury Limitations.

Notwithstanding any provisions to the contrary in Section 4 or elsewhere in any of the Loan Documents, Borrower shall not be obligated to pay interest at a rate which exceeds the maximum rate permitted by Law. If, but for this Section 20, Borrower would be deemed obligated to pay interest at a rate which exceeds the maximum rate permitted by Law, or if any of the Loan Obligations is paid or becomes payable before its originally scheduled Maturity and as a result Borrower has paid or would be obligated to pay interest at such an excessive rate, then (i) Borrower shall not be obligated to pay interest to the extent it exceeds the interest that would be payable at the maximum rate permitted by Law; (ii) if the outstanding Loan Obligations have not been accelerated as provided in Section 17.2.2, any such excess interest that has been paid by Borrower shall be refunded; (iii) if the outstanding Loan Obligations have been accelerated as provided in Section 17.2.2, any such exces s that has been paid by Borrower shall be applied to the Loan Obligations as provided in Section 17.2.9; and (iv) the effective rate of interest shall be deemed automatically reduced to the maximum rate permitted by Law.

General.

Lender's Right to Cure.

So long as there is an Existing Default, after first giving notice to Borrower, Lender may from time to time, in its absolute discretion, for Borrower's account and at Borrower's expense, pay or make a Revolving Loan Advance to pay any amount or do any act required of Borrower hereunder. So long as there is an Existing Default, Lender may also from time to time, in its absolute discretion, for Borrower's account and at Borrower's expense pay or make a Revolving Loan Advance to pay any amount or do any act reasonably requested by Lender to preserve, protect, maintain or enforce the Loan Obligations, the Collateral or Lenders' Security Interests therein and which Borrower fails to pay or do. Such payments and actions include payment of any judgment against Borrower, insurance premium, taxes or assessments, warehouse charge, finishing or processing charge, landlord's claim, and any other claim. All payments made by Lender pursuant to this Section and all out-of-pocket costs and expenses incurred by Lender in connection with any action taken by Lender hereunder shall be a part of the Loan Obligations, the repayment of which shall be secured by the Collateral. Any payment made or other action taken by Lender pursuant to this Section shall be without prejudice to any right to assert an Event of Default hereunder and to pursue Lender's other rights and remedies with respect thereto.

Rights Not Exclusive.

Every right granted to Lender hereunder or under any other Loan Document or allowed to it at law or in equity shall be deemed cumulative and may be exercised from time to time.

Survival of Agreements.

All covenants and agreements made herein and in the other Loan Documents shall survive the execution and delivery of this Agreement, the Notes and other Loan Documents and the making of every Advance. All agreements, obligations and liabilities of Borrower under this Agreement concerning the payment of money to Lender, including Borrower's obligations under Sections 21.4 and 21.5, but excluding the obligation to repay the Loans and interest accrued thereon, shall survive the indefeasible repayment in full of the Loans and interest accrued thereon, the return of the Notes to Borrower, and the termination of the Commitments.

Payment of Expenses.

Borrower agrees to pay or reimburse to Lender all of Lender's reasonable out-of-pocket costs incurred in connection with Lender's due diligence review before execution of the Loan Documents; the negotiation and preparation of any proposal, a commitment letter and the Loan Documents; the perfection of Lender's Security Interest in any Collateral, the interpretation of any of the Loan Documents; the enforcement of Lender's rights and remedies under the Loan Documents after a Default or Event of Default; any amendment of or supplementation to any of the Loan Documents; and any waiver, consent or forbearance with respect to any Default or Event of Default. Lender's reasonable out-of-pocket costs may include but are not limited to the following, to the extent they are actually paid or incurred by Lender: title insurance fees and premiums; the cost of searches for Security Interests existing against Covered Persons; recording and filing fees; appraisal fees; audit and exam fees; environmental consultant fees; l itigation costs; and all reasonable attorneys' and paralegals' expenses and reasonable fees; and all reasonable expenses incurred in connection with any of the foregoing. Attorneys' and paralegals' expenses may include but are not limited to filing charges; telephone, data transmission, facsimile and other communication costs; courier and other delivery charges; and photocopying charges. Litigation costs may include but are not limited to filing fees, deposition costs, expert witness fees, expenses of service of process, and other such costs paid or incurred in any administrative, arbitration, or court proceedings involving Lender and any Covered Person, including proceedings under the Federal Bankruptcy Code. All costs which Borrower is obligated to pay or reimburse Lender are Loan Obligations payable to Lender are Loan Obligations which are secured by the Collateral, and are payable on demand by Lender.

General Indemnity.

Indemnified Parties

Obligations Shall Survive

Indemnities Unenforceable

Letters of Credit.

Borrower assumes all risks (as against Lender, ABN Amro London, or any affiliate of either) of the acts or omissions of any beneficiary of the Construction Letter of Credit or any of the Letters of Credit, but Borrower retains any rights or claims that it may have against such beneficiary. Neither Lender nor any of its directors, officers, employees, agents, or representatives shall be liable or responsible for: (a) the use which may be made of the Construction Letter of Credit or any of the Letters of Credit or for any acts or omissions of beneficiary in connection therewith; (b) the validity, sufficiency or genuineness of documents, or of any endorsement(s) thereon, even if such documents should in fact prove to be in any or all respects invalid, insufficient, fraudulent or forged; (c) payment by Lender against presentation of documents which, on their face, appear to comply with the terms of the Construction Letter of Credit or any Letter of Credit, even though such documents may fail to bear any refer ence or adequate reference to the Construction Letter of Credit or any such Letter of Credit; or (d) any other circumstances whatsoever in making or failing to make payment under any Letter of Credit in connection with which Lender would, pursuant to the Uniform Customs and Practices for Documentary Credits (1993 Revision), International Chamber of Commerce Publication No. 500 (as amended from time to time), be absolved from liability. In furtherance and not in limitation of the foregoing, Lender may accept documents that appear on their face to be in order, without responsibility for further investigation, regardless of any notice or information to the contrary.

Changes in Accounting Principles.

If Borrower, at the end of its fiscal year and with the concurrence of its independent certified public accountants, changes the method of valuing the Inventory of Borrower, or if any other changes in accounting principles from those used in the preparation of any of the Financial Statements are required by or result from the promulgation of principles, rules, regulations, guidelines, pronouncements or opinions by the Financial Accounting Standards Board or the American Institute of Certified Public Accountants (or successors thereto or bodies with similar functions), and any of such changes result in a change in the method of calculation of, or affect the results of such calculation of, any of the financial covenants, standards or terms found herein, then the parties hereto agree to enter into and diligently pursue negotiations in order to amend such financial covenants, standards or terms so as to equitably reflect such changes, with the desired result that the criteria for evaluating the financial cond ition and results of operations of Borrower shall be the same after such changes as if such changes had not been made; provided, however, that until such changes are made, all financial covenants herein and all the provisions hereof which contemplate financial calculation hereunder shall remain in full force and effect.

Other Security and Guaranties.

Lender may, without notice or demand and without affecting Borrower's obligations hereunder, from time to time: (a) take from any Person and hold collateral (other than the Collateral) for the payment of all or any part of the Loan Obligations and exchange, enforce and release such collateral or any part thereof; and (b) accept and hold any endorsement or guaranty of payment of all or any part of the Loan Obligations and release or substitute any such endorser or guarantor, or any Person who has given any Security Interest in any other collateral as security for the payment of all or any part of the Loan Obligations, or any other Person in any way obligated to pay all or any part of the Loan Obligations.

Loan Records.

The date and amount of all Advances to Borrower and payments of amounts due from Borrower under the Loan Documents will be recorded in the records that Lender normally maintains for such types of transactions. The failure to record, or any error in recording, any of the foregoing shall not, however, affect the obligation of Borrower to repay the Loans and other amounts payable under the Loan Documents. Borrower shall have the burden of proving that such records are not correct. Borrower agrees that Lender's books and records showing the Loan Obligations and the transactions pursuant to this Agreement shall be admissible in any action or proceeding arising therefrom, irrespective of whether any Loan Obligation is also evidenced by a promissory note or other instrument. Such statement shall be deemed correct, accurate and binding on Borrower and an account stated (except for reversals and reapplications of payments as provided in Section 6.8 and corrections of errors discovered by Lender), unless Bor rower notifies Lender in writing to the contrary within 30 days after such statement is rendered. In the event a timely written notice of objections is given by Borrower, only the items to which exception is expressly made will be considered to be disputed by Borrower.

Loan Obligations Payable in Dollars.

All Loan Obligations that are payable in Dollars under the terms of the Loan Documents shall be payable only in Dollars. If, however, to obtain a judgment in any court it is necessary to convert a Loan Obligation payable in Dollars into another currency, the rate of exchange used shall be that at which Lender, using its customary procedures, could purchase Dollars with such other currency in New York, New York on the Business Day immediately preceding the day on which such judgment is rendered. If any sum in another currency is paid to Lender or received by Lender and applied to a Loan Obligation payable in Dollars, such Loan Obligation shall be deemed paid and discharged only to the extent of the amount of Dollars that Lender, using its customary procedures, is able to purchase in New York, New York with such sum on the Business Day immediately following receipt thereof. Borrower agrees to indemnify Lender against any loss in Dollars that it may incur on such Loan Obligation as a result of such payment o r receipt and application to such Loan Obligation.

Miscellaneous.

Notices.

All notices, consents, requests and demands to or upon the respective parties hereto shall be in writing, and shall be deemed to have been given or made when delivered in person to those Persons listed on the signature pages hereof or four days after being deposited in the United States mail, postage prepaid, or, in the case of overnight courier services, one Business Day after delivery to the overnight courier service, or in the case of telex or telecopy notice, when sent, verification received, in each case addressed as set forth on the signature pages hereof, or such other address as either party may designate by notice to the other in accordance with the terms of this Section. No notice given to or demand made on Borrower by Lender in any instance shall entitle Borrower to notice or demand in any other instance.

Confidentiality.

Except as provided in this Section, Lender agrees that it will not disclose to third parties any Confidential Information. For the purposes of this Section 22.2, "Confidential Information" means information delivered to Lender by or on behalf of Borrower or any Covered Person in connection with the transactions contemplated by or otherwise pursuant to this Agreement that is proprietary in nature and that was clearly marked or labeled or otherwise adequately identified when received by Lender as being confidential information of the Borrower or such Covered Person, provided that such term does not include information that (a) was publicly known or otherwise known by Lender prior to the time of such disclosure, (b) subsequently becomes publicly known through no act or omission by Lender or any person acting on behalf of Lender, (c) otherwise becomes known to Lender other than through disclosure by Borrower or any Covered Person or (d) constitutes Financial Statements or other information delivered to Lender as required hereunder that are otherwise publicly available. Lender will maintain the confidentiality of such Confidential Information in accordance with procedures adopted by Lender in good faith to protect Confidential Information delivered to Lender, provided that Lender may deliver or disclose Confidential Information to (i) its directors, officers, employees, agents, attorneys and affiliates (to the extent such disclosure reasonably relates to the administration of the Loans and the Loan Documents), (ii) its financial advisors and other professional advisors who agree to hold confidential the Confidential Information substantially in accordance with the terms of this Section, (iii) any proposed assignee, participant or transferee of Lender with respect to the Loans (if such Person has agreed in writing prior to its receipt of such Confidential Information to be bound by the provisions of this Section), (iv) any Governmental Authority having jurisdiction over Lender, or (v) any other Person to wh ich such delivery or disclosure may be necessary or appropriate (a) to effect compliance with any Law, rule, regulation or order applicable to Lender, (b) in response to any subpoena or other legal process, (c) in connection with any litigation to which Lender is a party, or (d) if an Event of Default has occurred and is continuing, to the extent Lender may reasonably determine such delivery and disclosure to be necessary or appropriate in the enforcement or for the protection of the rights and remedies under this Agreement or any other Loan Document.

Amendments, Waivers and Consents.

Unless otherwise provided herein, no amendment to or waiver of any provision of this Agreement, or of any of the other Loan Documents, nor consent to any departure by Borrower herefrom or therefrom, shall be effective unless it is in writing and signed by authorized officers of Borrower and Lender; provided, however, that any such amendment, waiver or consent shall be effective only in the specific instance and for the purpose for which given. No notice to or demand on Borrower in any instance shall entitle Borrower to any other or further notice or demand in another similar or different instance. No failure by Lender to exercise, and no delay by Lender in exercising, any right, remedy, power or privilege hereunder shall operate as a waiver thereof, nor shall any single or partial exercise by Lender of any right, remedy, power or privilege hereunder preclude any other exercise thereof, or the exercise of any other right, remedy, power or privilege existing under any Law or otherwise.

Rights Cumulative.

Each of the rights and remedies of Lender under this Agreement shall be in addition to all of its other rights and remedies under applicable Law, and nothing in this Agreement shall be construed as limiting any such rights or remedies.

Successors and Assigns.

This Agreement shall be binding upon and inure to the benefit of the parties hereto and all future holders of the Notes and their respective successors and assigns, except that Borrower may not assign, delegate or transfer any of its rights or obligations under this Agreement without the prior written consent of Lender. With respect to Borrower's successors and assigns, such successors and assigns shall include any receiver, trustee or debtor-in-possession of or for Borrower.

Severability.

Any provision of this Agreement which is prohibited, unenforceable or not authorized in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition, unenforceability or lack of authorization without invalidating the remaining provisions hereof or affecting the validity, enforceability or legality of such provision in any other jurisdiction unless the ineffectiveness of such provision would result in such a material change as to cause completion of the transactions contemplated hereby to be unreasonable.

Counterparts.

This Agreement may be executed by the parties hereto on any number of separate counterparts, and all such counterparts taken together shall constitute one and the same instrument. It shall not be necessary in making proof of this Agreement to produce or account for more than one counterpart signed by the party to be charged.

Governing Law; No Third Party Rights.

This Agreement, the other Loan Documents and the Notes and the rights and obligations of the parties hereunder and thereunder shall be governed by and construed and interpreted in accordance with the internal Laws of the State of Missouri applicable to contracts made and to be performed wholly within such state, without regard to choice or conflict of laws provisions; except that the provisions of the Loan Documents pertaining to the creation or perfection of Security Interests or the enforcement of rights of Lender in Collateral located in a State other than the State of Missouri, or in a country other than the United States, shall be governed by the laws of such other State or country, as applicable. This Agreement is solely for the benefit of the parties hereto and their respective successors and assigns, and no other Person shall have any right, benefit, priority or interest under, or because of the existence of, this Agreement.

Counterpart Facsimile Execution.

For purposes of this Agreement, a document (or signature page thereto) signed and transmitted by facsimile machine or telecopier is to be treated as an original document. The signature of any Person thereon, for purposes hereof, is to be considered as an original signature, and the document transmitted is to be considered to have the same binding effect as an original signature on an original document. At the request of any party hereto, any facsimile or telecopy document is to be re-executed in original form by the Persons who executed the facsimile or telecopy document. No party hereto may raise the use of a facsimile machine or telecopier or the fact that any signature was transmitted through the use of a facsimile or telecopier machine as a defense to the enforcement of this Agreement or any amendment or other document executed in compliance with this Section.

No Other Agreements.

There are no other agreements between Lender and Borrower, oral or written, concerning the subject matter of the Loan Documents, and all prior agreements concerning the same subject matter, including any proposal or Commitment Letter, are merged into the Loan Documents and thereby extinguished.

Negotiated Transaction.

Borrower and Lender represent each to the others that in the negotiation and drafting of this Agreement and the other Loan Documents they have been represented by and have relied upon the advice of counsel of their choice. Borrower and Lender affirm that their counsel have both had substantial roles in the drafting and negotiation of this Agreement and Lender affirms that its counsel has participated in the drafting and negotiation of this Agreement; therefore, this Agreement will be deemed drafted by all of Borrower and Lender and the rule of construction to the effect that any ambiguities are to be resolved against the drafter will not be employed in the interpretation of this Agreement.

Acknowledgment of Licensing Arrangements.

Nothing contained in this Agreement or in the Loan Documents shall be construed as prohibiting Borrower from entering into licensing or other contractual arrangements with respect to its software and patents for the purpose of creating revenue for Borrower in the ordinary course of Borrower's business as presently conducted.

CHOICE OF FORUM.

Subject only to the exception in the next sentence, Borrower, Tripos Realty and Lender hereby agree to the exclusive jurisdiction of the federal court of the Eastern District of Missouri and the state courts of Missouri located in St. Louis County, Missouri, and waive any objection based on venue or forum non conveniens with respect to any action instituted therein, and agree that any dispute concerning the relationship between Lender and Borrower or the conduct of any of them in connection with this Agreement or otherwise shall be heard only in the courts described above. Notwithstanding the foregoing: (1) Lender shall have the right to bring any action or proceeding against Borrower or its property in any courts of any other jurisdiction Lender deemS necessary or appropriate in order to realize on the Collateral, real estate, or other security for the Loan Obligations, and (2) each of the parties hereto acknowledges that any appeals from the courts described in the immediately preceding sentence may hav e to be heard by a court located outside those jurisdictions. Borrower shall cause each Covered Person to comply with the terms of this Section.

SERVICE OF PROCESS.

Each of Borrower and Tripos Realty hereby waive personal service of any and all process upon it and consents that all such service of process may be made by registered mail (return receipt requested) directed to Borrower at its address set forth on the signature pages hereof, and service so made shall be deemed to be completed five days after the same shall have been so deposited in the U.S. mails (or, if Lender has exercised its right to receive and open Borrower's mail as provided herein, on the date service of process is received by Borrower); or at Lender's option, by service upon CT Corporation, which Borrower and Tripos Realty irrevocably appoint as their respective agent for the purpose of accepting service of process within the State of Missouri. Lender shall promptly forward by registered mail any process so served upon said agent to Borrower at its address on the signature pages hereof. Nothing in this section shall affect the right of Lender to serve legal process in any other manner permitted by Law. Borrower shall cause each other Covered Person to agree to the terms of this Section.

JURY TRIAL.

Borrower, TRIPOS REALTY and Lender hereby waive any right to trial by jury of any claim, demand, action or cause of action (1) arising under this Agreement or any other Loan Document, or (2) in any way connected with or related or incidental to the dealings of the parties hereto or either of them in respect of this Agreement or any other Loan Document, or the transactions related hereto or thereto, in each case whether now existing or hereafter arising, and whether sounding in contract or tort or otherwise. Borrower, TRIPOS REALTY and Lender agree and consent that any such claim, demand, action or cause of action shall be decided by court trial without a jury and that either may file an original counterpart or a copy of this Agreement with any court as written evidence of the consent of the parties hereto to the waiver of their right to trial by jury. Borrower shall cause each other Covered Person to agree to the terms of this Section.

Incorporation By Reference.

All of the terms of the other Loan Documents are incorporated in and made a part of this Agreement by this reference.

Statutory Notice.

The following notice is given pursuant to Section 432.045 of the Missouri Revised Statutes; nothing contained in such notice shall be deemed to limit or modify the terms of the Loan Documents:

Statutory Notice-Insurance.

The following notice is given pursuant to Section 427.120 of the Missouri Revised Statutes; nothing contained in such notice shall be deemed to limit or modify the terms of the Loan Documents:

Amendment and Restatement.

The recitals to this Agreement are hereby incorporated into this Agreement, the truth and accuracy of which are evidenced by each party's execution hereof. This Agreement amends and restates, and Borrower and Tripos Realty expressly state that it does not constitute an extinguishment or novation of, the Loan Agreement dated as of April 30, 1999 by and among Borrower, Tripos Realty and Lender, as amended by a certain First Amendment to Loan and Security Agreement, dated as of June 30, 1999, as further amended by a certain Second Amendment to Loan and Security Agreement, dated as of March 8, 2000, as further amended by a certain Third Amendment to Credit Agreement, dated as of June 29, 2001, and as further amended by a certain Fourth Amendment to Loan Agreement, dated as of August 21, 2002 (as amended, the "Prior Loan Agreement", and all documents executed in connection therewith being the "Prior Loan Documents"), or the Prior Loan Documents, or constitute a release or relinquishment of the Security Interests granted to Lender in the Prior Loan Agreement or the Prior Loan Documents. This Agreement and each document executed in connection herewith, does not evidence or effect a refinancing of the loans under the Prior Loan Agreement or the Prior Loan Documents, or a waiver of Borrower's and Tripos Realty's obligation to reimburse Lender therefor or as otherwise set forth in the Prior Loan Agreement or the Prior Loan Documents, all as such obligations are amended and restated by this Agreement and the other Loan Documents.

[remainder of page intentionally blank]

IN WITNESS WHEREOF, the parties have caused this Agreement to be executed by appropriate duly authorized officers as of the date first above written.

TRIPOS, INC.

"Term Loan Maturity Date" -- December 2, 2005.

"Tripos Construction Reimbursement Agreement" -- shall mean that certain reimbursement agreement, dated as of the UK Effective Date and satisfactory to Lender, under which Tripos undertakes to reimburse to Lender on demand the amount of each draw on the Construction Letter of Credit.

THIS FIRST AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT ("First Amendment") is made and entered into as of this 16th day of October, 2003 by and among TRIPOS, INC., a Utah corporation ("Tripos"), TRIPOS REALTY, LLC, a Missouri limited liability company ("Tripos Realty;" Tripos and Tripos Realty are sometimes collectively referred to herein as the "Obligors"), and LASALLE BANK NATIONAL ASSOCIATION (the "Lender").

WHEREAS, pursuant to that certain Amended and Restated Loan Agreement, dated as of December 2, 2002, by and among the Obligors and Lender (as the same may be further amended, supplemented or otherwise modified from time to time, the "Loan Agreement"), Lender (i) established in favor of Tripos a revolving line of credit in the amount of $6,000,000, (ii) made a Term Loan  to Tripos in the amount of $4,350,000, (iii) established in favor of Tripos a Letter of Credit Commitment in an amount not to exceed $2,000,000; and (iv) established in favor of Tripos a Construction Letter of Credit Commitment in an amount not to exceed 1,773,750 British Pounds; and

WHEREAS, the Lender has agreed to the modification of certain provisions contained in the Loan Agreement and certain of the other Loan Documents upon the terms and conditions hereafter set forth.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements set forth herein and for other good and valuable consideration, the mutuality, receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. Definitions. All capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Loan Agreement.

2. Amendments to Loan Agreement. The Loan Agreement is hereby amended as follows:

(a) Article 3 of the Loan Agreement is hereby amended by adding to the end thereof the following new sections which shall read as follows:

"3.5 Interim Revolver Commitment.

3.5.1 Aggregate Amount; Reductions.

3.5.2 Limitation on Interim Revolver Advances.

3.5.3 Interim Revolver Note.

(b) Article 4 of the Loan Agreement is hereby amended by deleting Section 4.4 and replacing the same with the following:

(c) Article 4 of the Loan Agreement is hereby amended by adding new Section 4.5A which shall read as follows:

(d) Article 5 of the Loan Agreement is hereby amended by adding to the end thereof new Sections 5.6 and 5.7 which shall read as follows:

"5.6 First Amendment Fee.

(e) Article 6 of the Loan Agreement is hereby amended by deleting Section 6.2 in its entirety and replacing the same with the following:

"6.2 Scheduled Payments on Interim Revolver Loan.

6.2.1 Interest.

6.2.2 Principal.

(f) Article 6 of the Loan Agreement is hereby amended by deleting Section 6.5.1 in its entirety and replacing the same with the following:

(g) Sections 7.1, 7.3, 7.6, 7.8, 7.9 and 7.12 of the Loan Agreement are hereby deleted in their entireties and are hereby replaced with the following:

7.3 Revolving Loan Advances and Interim Revolver Advances.

7.3.1 Borrower Requests.

(k) Exhibit 2.1 (Glossary and Index of Defined Terms) to the Loan Agreement is hereby amended by adding in proper alphabetical position the following definition:

(l) The definitions of "Advance," "Commitment," "Eurodollar Loan," "Interest Period," "Loans," "Notes," and contained in Exhibit 2.1 (Glossary and Index of Defined Terms) to the Loan Agreement are hereby deleted in their entireties and are hereby replaced with the following:

(m) Exhibits 3.5.3 and 7.9A attached hereto are hereby added to the Loan Agreement.

(n) Within thirty (30) days of the date hereof, Borrower shall deliver a new Disclosure Schedule to Lender, which Disclosure Schedule shall be satisfactory to Lender in its sole discretion. Failure to deliver such schedule within such thirty (30) days or failure of such schedule to be, or to be revised to be, satisfactory to Lender within such thirty (30) days shall be an Event of Default.

3. Conditions to Effectiveness. This First Amendment shall become effective as of October 16, 2003, when and only when the Lender shall have received (i) this First Amendment duly executed by the Obligors, (ii) that certain Reaffirmation of Guaranty duly executed by Tripos Realty, (iii) that certain Second Modification to Deed of Trust, Assignment of Rents and Security Agreement duly executed by Tripos Realty (iv) the First Amendment Fee, (v) payment of all outstanding legal fees and costs of Lender, including those incurred in connection with this First Amendment have been properly authorized, (vi) evidence satisfactory to the Lender and its counsel that the transactions contemplated by the First Amendment have been properly authorized, and (vii) such other certificates, instruments, documents, agreements and opinions of counsel as may be required by Lender or its counsel, each of which shall be in form and substance satisfactory to Lender and its counsel.

4. Representations and Warranties. The Obligors hereby represent and warrant as follows:

(a) This First Amendment and the Loan Agreement, amended hereby, constitute legal, valid and binding obligations of the Obligors and are enforceable against the Obligors in accordance with their respective terms, except to the extent that the enforceability thereof against such Covered Person may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally or by equitable principles of general application.

(b) Upon the effectiveness of this First Amendment, the Obligors hereby reaffirm all covenants, representations and warranties made in the Loan Agreement to the extent the same are not amended hereby and agrees that all such covenants, representations and warranties shall be deemed to have been remade as of the effective date of this First Amendment.

(c) No Event of Default or Default has occurred and is continuing or would exist after giving effect to this First Amendment.

(d) The Covered Persons have no defense, counterclaim or offset with respect to the Loan Agreement or any of the other Loan Documents.

5. Effect on the Loan Agreement.

(a) Upon the effectiveness of this First Amendment, each reference in the Loan Agreement to "this Agreement," "hereunder," "hereof," "herein" or words of like import shall mean and be a reference to the Loan Agreement as amended hereby.

(b) Except as specifically amended herein, the Loan Agreement, the Loan Documents, and all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed.

(c) The execution, delivery and effectiveness of this First Amendment shall not operate as a waiver of any right, power or remedy of Lender, nor constitute a waiver of any provision of the Loan Agreement, the Loan Documents, or any other documents, instruments or agreements executed and/or delivered under or in connection therewith.

6. Limited Effectiveness of First Amendment. Once the Interim Revolver Maturity Date has expired, the terms of this First Amendment shall expire and the Loan Agreement shall continue in full force and effect as if this First Amendment had not been executed and entered into.

7. Governing Law. This First Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns and shall be governed by and construed in accordance with the laws of the State of Missouri.

8. Headings. Section headings in this First Amendment are included herein for convenience of reference only and shall not constitute a part of this First Amendment for any other purpose.

9. Counterparts. This First Amendment may be executed by the parties hereto in one or more counterparts, each of which taken together shall be deemed to constitute one and the same instrument.

IN WITNESS WHEREOF, this First Amendment has been duly executed as of the day and year first written above.

TRIPOS, INC.

By: _________________________________

Name: B. James Rubin

Title: Senior Vice President & Chief

Financial Officer

TRIPOS REALTY, LLC

(as Obligor and acknowledged as Guarantor)

By: TRIPOS, INC., its sole member

By: ________________________________

Name: B. James Rubin

Title: Senior Vice President & Chief

Financial Officer

LASALLE BANK NATIONAL ASSOCIATION

By: ________________________________

Name:

Title:

THIS SECOND AMENDMENT TO AMENDED AND RESTATED LOAN AGREEMENT ("Second Amendment") is made and entered into as of this 19^th day of April, 2004 by and among TRIPOS, INC., a Utah corporation ("Tripos"), TRIPOS REALTY, LLC, a Missouri limited liability company ("Tripos Realty;" Tripos and Tripos Realty are sometimes collectively referred to herein as the "Obligors"), and LASALLE BANK NATIONAL ASSOCIATION (the "Lender").

WHEREAS, pursuant to that certain Amended and Restated Loan Agreement, dated as of December 2, 2002, by and among the Obligors and Lender, Lender (i) established in favor of Tripos a revolving line of credit in the amount of $6,000,000, (ii) made a Term Loan  to Tripos in the amount of $4,350,000, (iii) established in favor of Tripos a Letter of Credit Commitment in an amount not to exceed $2,000,000; and (iv) established in favor of Tripos a Construction Letter of Credit Commitment in an amount not to exceed 1,773,750 British Pounds, as amended by that certain First Amendment to Amended and Restated Loan Agreement, dated as of October 16, 2003, by and among Obligors and Lender, pursuant to which Lender established in favor of Tripos an interim revolving line of credit in the amount of $4,000,000 (as the same may be further amended, supplemented or otherwise modified from time to time, the "Loan Agreement"); and

WHEREAS, the Lender has agreed to the modification of certain provisions contained in the Loan Agreement and certain of the other Loan Documents upon the terms and conditions hereafter set forth.

NOW, THEREFORE, in consideration of the premises and the mutual covenants and agreements set forth herein and for other good and valuable consideration, the mutuality, receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:

1. Definitions. All capitalized terms not otherwise defined herein shall have the meanings given to such terms in the Loan Agreement.

2. Amendments to Loan Agreement. The Loan Agreement is hereby amended as follows:

(a) Article 3 of the Loan Agreement is hereby amended by:

(iv) deleting Section 3.5 in its entirety.

(b) Section 4.2 (Interest on Draws on Construction Letter of Credit) of the Loan Agreement is hereby deleted it in its entirety.

(c) Section 4.5 (Increments) of the Loan Agreement is hereby amended and restated to read as follows:

(d) Section 4.5A (Increments) is hereby deleted in its entirety.

(e) Section 4.9 (Rate After Maturity) of the Loan Agreement is hereby amended and restated as follows:

(f) Section 5.3 (Letter of Credit Fees) of the Loan Agreement is hereby amended by deleting the phrase, "(other than the Construction Letter of Credit)" from the first and second lines thereof:

(g) Section 5.4 (Construction Letter of Credit Fees) of the Loan Agreement is hereby deleted in its entirety.

(h) Section 5.7 (Unused Interim Revolver Fee) of the Loan Agreement is hereby deleted in its entirety.

(i) Section 6.2 (Scheduled Payments on Interim Revolver Loan) of the Loan Agreement is hereby deleted in its entirety.

(j) Section 6.4 (Reimbursement Obligations) of the Loan Agreement is hereby amended by deleting the phrase "the Construction Letter of Credit" and the word "other" from the second line thereof.

(k) Section 7.2 (Borrowing Base Certificates) of the Loan Agreement is hereby deleted in its entirety.

(l) Section 7.4 (Letters of Credit) of the Loan Agreement is hereby amended by deleting the phrase "the Construction Letter of Credit or" from the first and fourth lines thereof and by deleting the word "other" from the fourth line thereof.

(m) Section 7.6. "Restrictions on Advances." of the Loan Agreement is hereby amended and restated to read as follows:

"7.6. Restrictions on Advances.

(n) Section 8.1 (Deed of Trust Modification; Mortgage) of the Loan Agreement is hereby amended by deleting the phrase "On the UK Effective Date, the LaSalle UK Mortgage, satisfactory to Lender, and, on" in the first line and substituting "On".

(o) Section 10.1 (Conditions to Effectiveness of Amended and Restated Loan Agreement and Construction Letter of Credit) of the Loan Agreement is hereby amended by deleting the introductory clause in its entirety and replacing it with the following:

(p) Section 10.1.4 (Perfection of Security Interests) of the Loan Agreement is hereby amended and restated to read as follows:

(q) Article 11 (Additional Conditions to Issuance of Letters of Credit) of the Loan Agreement is hereby amended as follows:

(r) Article 14 (Affirmative Covenants) of the Loan Agreement is hereby amended by deleting the phrase "the Construction Letter of Credit or" from the first and second lines thereof:

(s) Article 15 (Negative Covenants) of the Loan Agreement is hereby amended by deleting the phrase ", including without limitation the Construction Letter of Credit" from the second line thereof:

(t) Section 15.3.2 (The Loan Obligations and the UK Loan Obligations) of the Loan Agreement is hereby amended and restated to read as follows:

(u) Section 15.4.5 (Securing Payment) of the Loan Agreement is hereby amended by deleting the phrase "(other than the Indebtedness evidenced by the UK Loan Documents)".

(v) Section 15.4.11 (Security Interest to Secure Loan Obligations and UK Loan Obligations) of the Loan Agreement is hereby amended and restated to read as follows:

(y) Section 15.9 (Indirect Obligations) of the Loan Agreement is hereby amended by deleting the phrase "or UK Loan Obligations (or with respect to such obligations)".

(z) The definition of "EBITDA" under Section 16.1 (Special Definitions) is hereby amended (A) by changing the name of such defined term to "EBIT" and (B) by deleting the reference to "depreciation and amortization expense".

(aa) The definition of "Fixed Charges" under Section 16.1 (Special Definitions) is hereby deleted in its entirety.

(bb) Sections 16.2, 16.3 and 16.4 of the Loan Agreement are hereby deleted in their entirety.

(cc) Section 16.5 of the Loan Agreement (Minimum EBITDA) is hereby amended and restated as follows:

"16.5 Minimum Interest Coverage.

Borrower covenants and agrees that the ratio of Borrower's EBIT to Borrower's Interest Expense for the preceding twelve (12) month period calculated for March 31, 2004, and for the last day of each fiscal quarter thereafter, shall at no time be less than 1.75 to 1.00."

(dd) Section 16.7 of the Loan Agreement (Minimum Shareholders Equity) is hereby amended and restated as follows:

(ee) Section 17.1.3 of the Loan Agreement (Failure to Pay Accounts Owed to Other Persons) is hereby amended by deleting the phrase "including without limitation, UK Loan Obligations".

(ff) Section 17.1.16 of the Loan Agreement (Cross Default) is hereby amended by deleting the last sentence thereof.

(gg) Section 17.1.19 of the Loan Agreement (Construction Letter of Credit) is hereby deleted in its entirety.

(hh) Section 21.6. "Letters of Credit." of the Loan Agreement is hereby amended and restated to read as follows:

(ii) The following definitions contained in Exhibit 2.1. (Glossary And Index Of Defined Terms) to the Loan Agreement are hereby deleted:

1. "Borrowing Base Certificate"
2. "Eligible Accounts"
3. "Eligible License Receivables"
4. "Eligible License Receivables Debtor"
5. "Net Eligible Accounts"
6. "Non-Financed Capital Expenditures" and
7. "UK Guaranty".

(jj) The following definitions contained in Exhibit 2.1 (Glossary And Index Of Defined Terms) to the Loan Agreement are hereby amended and restated to read as follows:

(kk) The definition of "Second Amendment Fee" shall be added to Exhibit 2.1 (Glossary And Index Of Defined Terms) to the Loan Agreement as follows:

(ll) Schedule II to the Form of Compliance Certificate in Exhibit 14.14.2 to the Loan Agreement is hereby amended and restated as attached to this Second Amendment.

3. Each of Borrowers and Lender acknowledges that the Interim Revolving Note and Interim Revolver Commitment, created pursuant to the First Amendment to Amended and Restated Loan Agreement dated as of October 16, 2003, which expired as of February 13, 2004, and the commitments and advances for such facility have terminated.

4. Within thirty (30) days of the date hereof, Borrower shall deliver a new Disclosure Schedule to Lender, which Disclosure Schedule shall be satisfactory to Lender in its sole discretion. Failure to deliver such schedule within such thirty (30) days or failure of such schedule to be, or to be revised to be, satisfactory to Lender within such thirty (30) days shall be an Event of Default.

5. Waiver of Minimum Shareholders Equity Covenant. Without waiving any Events of Default related to any other requirements of the Loan Agreement, the Lender hereby waives Obligors' noncompliance with Section 16.7 of the Loan Agreement (Minimum Shareholders Equity) for the period ended December 31, 2003 only. Such waiver shall not release Obligors from the Minimum Shareholders Equity covenant for any other period or from any other covenants under the Loan Agreement.

6. Conditions to Effectiveness. This Second Amendment shall become effective as of April 19, 2004, when and only when the Lender shall have received (i) this Second Amendment duly executed

by the Obligors, (ii) that certain Reaffirmation of Guaranty duly executed by Tripos Realty, (iii) the Second Amendment Fee, (iv) payment of all outstanding legal fees and costs of Lender, including those incurred in connection with this Second Amendment have been properly authorized, (v) evidence satisfactory to the Lender and its counsel that the transactions contemplated by the Second Amendment have been properly authorized, and (vi) such other certificates, instruments, documents, agreements and opinions of counsel as may be required by Lender or its counsel, each of which shall be in form and substance satisfactory to Lender and its counsel. Subject to this Section 6, effective as of the date hereof Lender hereby terminates the UK Loan Obligations to which it is a party.

7. Representations and Warranties. The Obligors hereby represent and warrant as follows:

(a) This Second Amendment and the Loan Agreement, amended hereby, constitute legal, valid and binding obligations of the Obligors and are enforceable against the Obligors in accordance with their respective terms, except to the extent that the enforceability thereof against such Covered Person may be limited by bankruptcy, insolvency, reorganization, moratorium or similar Laws affecting creditors' rights generally or by equitable principles of general application.

(b) Upon the effectiveness of this Second Amendment, the Obligors hereby reaffirm all covenants, representations and warranties made in the Loan Agreement to the extent the same are not amended hereby and agrees that all such covenants, representations and warranties shall be deemed to have been remade as of the effective date of this Second Amendment.

(c) After giving effect to the waiver provided under Section 3 hereof, no Event of Default or Default has occurred and is continuing or would exist after giving effect to this Second Amendment.

(d) The Covered Persons have no defense, counterclaim or offset with respect to the Loan Agreement or any of the other Loan Documents.

8. Effect on the Loan Agreement.

(a) Upon the effectiveness of this Second Amendment, each reference in the Loan Agreement to "this Agreement," "hereunder," "hereof," "herein" or words of like import shall mean and be a reference to the Loan agreement as amended hereby.

(b) Except as specifically amended herein, the Loan Agreement, the Loan Documents, and all other documents, instruments and agreements executed and/or delivered in connection therewith, shall remain in full force and effect, and are hereby ratified and confirmed.

(c) Except as expressly provided under Section 3 hereof, the execution, delivery and effectiveness of this Second Amendment shall not operate as a waiver of any right, power or remedy of Lender, nor constitute a waiver of any provision of the Loan Agreement, the Loan Documents, or any other documents, instruments or agreements executed and/or delivered under or in connection therewith.

9. Governing Law. This Second Amendment shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns and shall be governed by and construed in accordance with the laws of the State of Missouri.

10. Headings. Section headings in this Second Amendment are included herein for convenience of reference only and shall not constitute a part of this Second Amendment for any other purpose.

11. Counterparts. This Second Amendment may be executed by the parties hereto in one or more counterparts, each of which taken together shall be deemed to constitute one and the same instrument.

IN WITNESS WHEREOF, this Second Amendment has been duly executed as of the day and year first written above.

TRIPOS, INC.

By: _________________________________

Name: B. James Rubin

Title: Senior Vice President & Chief

Financial Officer

TRIPOS REALTY, LLC

(as Obligor and acknowledged as Guarantor)

By: TRIPOS, INC., its sole member

By: ________________________________

Name: B. James Rubin

Title: Senior Vice President & Chief

Financial Officer

LASALLE BANK NATIONAL ASSOCIATION

By: ________________________________

Name: Tom Harmon

Title: Vice President